KR102022279B1 - A composition comprising an extract of Angelica keiskei for treating and preventing muscle-related disorder - Google Patents
A composition comprising an extract of Angelica keiskei for treating and preventing muscle-related disorder Download PDFInfo
- Publication number
- KR102022279B1 KR102022279B1 KR1020180125971A KR20180125971A KR102022279B1 KR 102022279 B1 KR102022279 B1 KR 102022279B1 KR 1020180125971 A KR1020180125971 A KR 1020180125971A KR 20180125971 A KR20180125971 A KR 20180125971A KR 102022279 B1 KR102022279 B1 KR 102022279B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- muscle
- compound
- present
- differentiation
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 88
- 241001105098 Angelica keiskei Species 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 title abstract description 42
- 210000003205 muscle Anatomy 0.000 title abstract description 42
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 14
- 206010006895 Cachexia Diseases 0.000 claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 230000002265 prevention Effects 0.000 claims description 13
- 239000000469 ethanolic extract Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 abstract description 72
- 230000004069 differentiation Effects 0.000 abstract description 48
- 239000000052 vinegar Substances 0.000 abstract description 44
- 235000021419 vinegar Nutrition 0.000 abstract description 44
- 210000004027 cell Anatomy 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 41
- 210000003098 myoblast Anatomy 0.000 abstract description 34
- 238000002474 experimental method Methods 0.000 abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 23
- 230000001965 increasing effect Effects 0.000 abstract description 23
- 201000010099 disease Diseases 0.000 abstract description 21
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 abstract description 19
- 230000002103 transcriptional effect Effects 0.000 abstract description 17
- 101100239693 Dictyostelium discoideum myoD gene Proteins 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 12
- 201000000585 muscular atrophy Diseases 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract description 9
- 238000011156 evaluation Methods 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 8
- 208000001076 sarcopenia Diseases 0.000 abstract description 8
- 206010003591 Ataxia Diseases 0.000 abstract description 7
- 206010028289 Muscle atrophy Diseases 0.000 abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 abstract description 7
- 208000029578 Muscle disease Diseases 0.000 abstract description 6
- 208000021642 Muscular disease Diseases 0.000 abstract description 6
- 201000009623 Myopathy Diseases 0.000 abstract description 6
- 235000015872 dietary supplement Nutrition 0.000 abstract description 6
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 238000012545 processing Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 56
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 229940125782 compound 2 Drugs 0.000 description 14
- 229940125898 compound 5 Drugs 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 229940093499 ethyl acetate Drugs 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- -1 6,7-dihydroxy-3,7-dimethyl-2-octenyl Chemical group 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000012454 non-polar solvent Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 239000000287 crude extract Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LRSMBOSQWGHYCW-MDGZPELGSA-N (e)-1-[3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound CC(C)=CCC\C(C)=C\CC1=C(O)C=CC(C(=O)\C=C\C=2C=CC(O)=CC=2)=C1O LRSMBOSQWGHYCW-MDGZPELGSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- LRSMBOSQWGHYCW-OAEBONLZSA-N Xanthoangelol Natural products CC(C)=CCC\C(C)=C/CC1=C(O)C=CC(C(=O)\C=C\C=2C=CC(O)=CC=2)=C1O LRSMBOSQWGHYCW-OAEBONLZSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- DUWPGRAKHMEPCM-IZZDOVSWSA-N isobavachalcone Chemical compound CC(C)=CCC1=C(O)C=CC(C(=O)\C=C\C=2C=CC(O)=CC=2)=C1O DUWPGRAKHMEPCM-IZZDOVSWSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000001114 myogenic effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- LRSMBOSQWGHYCW-UHFFFAOYSA-N xanthoangerol Natural products CC(C)=CCCC(C)=CCC1=C(O)C=CC(C(=O)C=CC=2C=CC(O)=CC=2)=C1O LRSMBOSQWGHYCW-UHFFFAOYSA-N 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 102000008934 Muscle Proteins Human genes 0.000 description 5
- 108010074084 Muscle Proteins Proteins 0.000 description 5
- 108010056785 Myogenin Proteins 0.000 description 5
- 102000004364 Myogenin Human genes 0.000 description 5
- YSOKENZJQWPLRA-UXBLZVDNSA-N Xanthoangelol D Chemical compound OC1=C(CC(O)C(C)=C)C(OC)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 YSOKENZJQWPLRA-UXBLZVDNSA-N 0.000 description 5
- 210000004262 dental pulp cavity Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 210000000107 myocyte Anatomy 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000002798 polar solvent Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- QYRLSMGUZOLLIP-UHFFFAOYSA-N xanthoangelol D Natural products CC(=C)CC(O)c1c(O)ccc(C(=O)C=Cc2ccc(O)cc2)c1O QYRLSMGUZOLLIP-UHFFFAOYSA-N 0.000 description 5
- XBFSDEKOTLYPJU-SXZUIPJJSA-N (e)-1-[3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2-hydroxy-4-methoxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound OC1=C(C\C=C(/C)CCC=C(C)C)C(OC)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 XBFSDEKOTLYPJU-SXZUIPJJSA-N 0.000 description 4
- XDKYBPGIBVMHHB-UHFFFAOYSA-N 4-Hydroxyderricin Natural products OC1=C(CC=C(C)C)C(OC)=CC=C1C(=O)C=CC1=CC=C(O)C=C1 XDKYBPGIBVMHHB-UHFFFAOYSA-N 0.000 description 4
- XDKYBPGIBVMHHB-KPKJPENVSA-N 4-Hydroxyderricin Chemical compound OC1=C(CC=C(C)C)C(OC)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 XDKYBPGIBVMHHB-KPKJPENVSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001788 chalcone derivatives Chemical class 0.000 description 4
- 235000005513 chalcones Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 230000004070 myogenic differentiation Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- XBFSDEKOTLYPJU-DMCBTGHKSA-N xanthoangelol F Natural products O=C(/C=C/c1ccc(O)cc1)c1c(O)c(C/C=C(\CC/C=C(\C)/C)/C)c(OC)cc1 XBFSDEKOTLYPJU-DMCBTGHKSA-N 0.000 description 4
- NCHZAFAGBAEJJJ-BAYITLGHSA-N (e)-1-[2,4-dihydroxy-3-[(2e)-6-hydroxy-3,7-dimethylocta-2,7-dienyl]phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound CC(=C)C(O)CC\C(C)=C\CC1=C(O)C=CC(C(=O)\C=C\C=2C=CC(O)=CC=2)=C1O NCHZAFAGBAEJJJ-BAYITLGHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- NCHZAFAGBAEJJJ-CXECKHGTSA-N Xanthoangelol B Natural products O=C(/C=C/c1ccc(O)cc1)c1c(O)c(C/C=C(\CC[C@H](O)C(=C)C)/C)c(O)cc1 NCHZAFAGBAEJJJ-CXECKHGTSA-N 0.000 description 3
- QJCKCZSARZRFFO-KHGCLOSWSA-N Xanthokeismin A Natural products O=C(/C=C/c1ccc(O)cc1)c1c(O)c(C/C=C(\C/C=C/C(O)(C)C)/C)c(O)cc1 QJCKCZSARZRFFO-KHGCLOSWSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- AJERVVHSERWGFL-UXBLZVDNSA-N (e)-1-[3-(2-hydroperoxy-3-methylbut-3-enyl)-2-hydroxy-4-methoxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound OC1=C(CC(OO)C(C)=C)C(OC)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 AJERVVHSERWGFL-UXBLZVDNSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 241000125175 Angelica Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101001023028 Gallus gallus Myogenin Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DYPZZHZYUZHEFW-UHFFFAOYSA-N Xanthoangelol E Natural products COc1ccc(C(=O)C=Cc2ccc(O)cc2)c(O)c1C(CC(=C)C)OO DYPZZHZYUZHEFW-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100290713 Caenorhabditis elegans mef-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108700011215 E-Box Elements Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 108010010416 Myogenic Regulatory Factors Proteins 0.000 description 1
- 102000015864 Myogenic Regulatory Factors Human genes 0.000 description 1
- 102100038380 Myogenic factor 5 Human genes 0.000 description 1
- 101710099061 Myogenic factor 5 Proteins 0.000 description 1
- 102000004472 Myostatin Human genes 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000219098 Parthenocissus Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- YKEKYBOBVREARV-UHFFFAOYSA-N pentanedioic acid Chemical compound OC(=O)CCCC(O)=O.OC(=O)CCCC(O)=O YKEKYBOBVREARV-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000000419 skeletal muscle satellite cell Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
본 발명은 신선초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 근육관련 질환의 예방 및 치료용 조성물에 대한 것이다. 본 발명의 신선초 추출물을 대상으로 (1) myoD 전사활성(transcriptional activity)을 측정하는 근원세포의 분화촉진 효능 평가법(실험예 1)을 통하여 MyoD 전사 활성(transcriptional activity)을 유의적으로 증가시키고 분화된 C2C12 세포에서의 MHC 발현을 촉진함을 확인하였으며; (2) 근원세포 분화(myoblast differentiation) 에 미치는 영향 실험 (실험예 2)을 통하여 시료 처리에 의하여 실린더 형(cylinder-shaped) 다핵성 근관세포(multinucleated myotubes) 수를 증가시켰고, 다핵성 근관세포 (multinuclear myotubes)의 비율을 증가시켜, 근관세포를 형성하는 근원세포 분화를 촉진시킴을 입증하였는 바, 이러한 상기 실험 결과는 본 발명의 신선초 추출물이 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근경직증, 위축성 축삭경화증, 근무력증, 악액질 (cachexia) 및 노인성근육감소증(sarcopenia) 등의 근육 질환 치료제 또는 보조제로 사용 가능함을 확인함으로써, 상기 조성물을 근육질환의 예방 및 치료용 약학조성물, 건강기능식품 및 건강보조식품 등으로 유용하게 이용될 수 있다.The present invention relates to a composition for the prophylaxis and treatment of muscle-related diseases containing fresh vinegar extract or a compound isolated therefrom as an active ingredient. (1) Significantly increased MyoD transcriptional activity and differentiated it through (1) MyoD transcriptional activity evaluation method (Experimental Example 1), which measures myoD transcriptional activity of the fresh vinegar extract of the present invention. It was found to promote MHC expression in C2C12 cells; (2) Effect on myoblast differentiation The number of cylinder-shaped multinucleated myotubes was increased by sample processing through experiments (Experimental Example 2), and multinucleated myotubes ( Increasing the ratio of multinuclear myotubes, it has been proved to promote myoblast differentiation to form myotubes, the results of the above experiments showed that the extract of the present invention is atony, muscle atrophy, muscular dystrophy The composition can be used as a therapeutic agent or adjuvant for muscle diseases such as muscle dystrophy, muscle degeneration, myopathy, atrophic atrophy, ataxia, cachexia and sarcopenia. It can be usefully used as a therapeutic pharmaceutical composition, health functional food and health supplement food.
Description
본 발명은 신선초 추출물 또는 이로부터 분리된 화합물을 함유하는 근육관련 질환의 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of muscle-related diseases containing fresh vinegar extract or a compound isolated therefrom.
[문헌 1] J Cachexia Sarcopenia Muscle. 2015, 6, 197Document 1 J Cachexia Sarcopenia Muscle. 2015, 6, 197
[문헌 2] Pharmacol Res. 2015, 99, 86
[문헌 3] Pharmacol. Res. 2015, 99, 86100
[문헌 4] The Korea Journal of Sports Science 2011, 30, 1551[Ref. 4] The Korea Journal of Sports Science 2011, 30, 1551
[문헌 5] J Biol. Chem 278:40717-40722, 2003Document 5 J Biol. Chem 278: 40717-40722, 2003
[문헌 6] Cell Mol Life Sci 70: 4117-4130, 2013
[문헌 7] Sci Signal 6: re2, 2013Sci Signal 6: re2, 2013
[문헌 8] Langley, B.; Thomas, M.; Bishop, A.; Sharma, M.; Gilmour, S.; Kambadur, R. J. Biol. Chem. 2002, 277, 498318 Langley, B .; Thomas, M .; Bishop, A .; Sharma, M .; Gilmour, S .; Kambadur, R. J. Biol. Chem. 2002, 277, 49831
[문헌 9] Biol. Chem 2004, 279, pp.52643
[문헌 10] Eur J Histochem. 2004, 48, 223-3310 Eur J Histochem. 2004, 48, 223-33
[문헌 11] Chem. Biol. Interact. 2016, 248, 6011 Chem. Biol. Interact. 2016, 248 , 60
[문헌 12] Histochem. Cell Biol. 2012, 138, p.187; 12. Histochem. Cell Biol. 2012 , 138, p. 187;
[문헌 13] J. Cell Physiol. 2010, 224, p713 J. Cell Physiol. 2010 , 224, p7
[문헌 14] J. Biol. Chem 2004, 279, 5264314 J. Biol. Chem 2004, 279 , 52643
[문헌 15] Chem. Biol. Interact. 2016, 248, 60.
[문헌 16] Sci Rep. 2016, 11, 24214. doi: 10.1038/srep24214 16 Sci Rep. 2016, 11, 24214.doi: 10.1038 / srep24214
본 발명은 신선초 추출물 또는 이로부터 분리된 화합물을 함유하는 근육관련 질환의 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of muscle-related diseases containing fresh vinegar extract or a compound isolated therefrom.
근육재생(Muscle regeneration)은 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근경직증, 근위축성 축삭경화증, 근무력증, 악액질 (cachexia) 및 노인성근육감소증(sarcopenia)과 같은 골격근 퇴행 질환을 극복하는 목적으로 주목되어 왔다. (J Cachexia Sarcopenia Muscle. 2015, 6, 197)Muscle regeneration includes atony, muscular atrophy, muscular dystrophy, muscle degeneration, myopathy, muscular atrophy, ataxia, cachexia and sarcopenia It has been noted for the purpose of overcoming skeletal muscle degenerative diseases such as. ( J Cachexia Sarcopenia Muscle. 2015, 6, 197)
근육의 진행성 약화 및 기능 소실은 삶의 질을 위협하고 암환자의 생존율을 저하시킨다. 암환자 중 30% 이상이 근육 소실에 의한 체중 감소로 인하여 사망한다. 이러한 근육 기능 소실은 미오-단백질(myo-proteins) 변성 및 근섬유의 단면적(muscle fiber cross-sectional area), 근 강도(muscle strength), 근섬유 숫자(nuclear number of myofibers) 및 인슐린 반응성(insulin responsiveness) 감소 등을 공통적으로 동반한다.Progressive weakness and loss of function threaten the quality of life and reduce the survival of cancer patients. More than 30% of cancer patients die from weight loss due to muscle loss. This loss of muscle function is due to myo-proteins degeneration and decreased muscle fiber cross-sectional area, muscle strength, muscle number of myofibers and insulin responsiveness. It is accompanied by common.
암 이외에도 근육 손실은 노화의 진행과 다양한 만성 질환에 의해서도 야기될 수 있다. 노화가 진행됨에 따라, 새롭게 생성되는 골격근의 일부가 섬유 조직으로 대체되면서 인체의 골격 근육량 및 강도가 감소되는 근육감소증이 나타난다. 또한, 고혈압, 내당능 장애 (impaired glucose tolerance) 및 당뇨, 비만, 이상지질혈증, 아테롬성 경화증 및 심혈관 질환 등 연령이 증가할수록 발병률이 증가되는 만성 질환에서도 근육 손실이 나타난다. (Pharmacol Res. 2015, 99, 86).In addition to cancer, muscle loss can also be caused by the progression of aging and various chronic diseases. As aging progresses, some of the newly created skeletal muscles are replaced with fibrous tissues, resulting in sarcopenia, which reduces the body's skeletal muscle mass and strength. In addition, muscle loss also occurs in chronic diseases in which the incidence increases with age, such as hypertension, impaired glucose tolerance, and diabetes, obesity, dyslipidemia, atherosclerosis, and cardiovascular disease. ( Pharmacol Res. 2015 , 99 , 86).
근육 퇴행증치료 전략은 염증성 분자 및 미오스타틴(myostatin)의 억제 또는 시클릭(cyclic) AMP, PGC (proliferator-activated receptor gamma coactivator)-1α 및 인슐린 신호 전달계의 활성화 등이 있다. 다수의 잠재적 약물들이 개발되었음에도 불구하고, 미국 식약청에서 승인된 근위축증 치료제로는 메게스테롤 아세테이트(megestrol acetate)가 유일하다. 근육퇴행증 치료 및 예방을 위한 약물들은 근육 단백질 이화작용(protein catabolism)을 저해하거나 또는 위성세포 기능(satellite cell functions)을 증진시키는 활성을 나타낸다. (Pharmacol. Res. 2015, 99, 86100).Strategies for the treatment of muscle degeneration include the inhibition of inflammatory molecules and myostatin or the activation of cyclic AMP, proliferator-activated receptor gamma coactivator (PGC) -1α and the insulin signaling system. Although a number of potential drugs have been developed, megestrol acetate is the only drug approved by the US Food and Drug Administration. Drugs for the treatment and prevention of myopathy exhibit activity that inhibits muscle protein catabolism or enhances satellite cell functions. ( Pharmacol. Res. 2015, 99, 86100).
근육에서는 동화작용과 이화작용이 균형을 이루며 근육 생성을 조절하는데, 이 때 근육 세포 내에서는 이와 관련하여 여러 생체 신호전달 과정이 조절된다. 근육 단백질의 분해보다 합성을 유도하는 신호전달 반응이 활성화 될 경우, 근육 단백질의 합성이 증가되어 근육 크기 증가(hypertrophy, 근비대)나 근섬유 수 증가 (hyperplasia)를 유도하여 과도한 근육 생성을 초래한다 (The Korea Journal of Sports Science 2011, 30, 1551). In muscle, assimilation and catabolism are balanced and regulate muscle production. In this context, many biological signaling processes are regulated in muscle cells. When the signaling response that induces synthesis is activated rather than the degradation of muscle proteins, the synthesis of muscle proteins is increased, leading to increased muscle size (hypertrophy) or increased muscle fiber (hyperplasia) resulting in excessive muscle production (The Korea Journal of Sports Science 2011, 30, 1551).
근육 생성 유도 인자들은 근 세포 내에서 PI3K(phosphatidylinositol-3 kinase)/Akt 경로를 활성화 시키고 그에 따라 하위 단계의 단백질을 인산화함으로써 근육 단백질 합성을 유도한다. 이 중 PI3K/Akt 신호전달에 의한 mTOR(mammalian target of rapamycin)의 활성은 세포 내에서 다양한 성장 신호를 통합하는 중심 성장신호전달 기전으로 인정되고 있다. mTOR가 활성화되면 두 개의 하위 타겟인 4EBP1(4E-binding protein)과 p70S6K(phosphorylated 70-kDa ribosomal S6 kinase)가 활성화됨으로써, 근육 단백질 합성이 유도되어 근육량이 증가한다 (The Korea Journal of Sports Science 30: 1551-1561, 2011, J Biol. Chem 278:40717-40722, 2003).Muscle induction factors induce muscle protein synthesis by activating the PI3K (phosphatidylinositol-3 kinase) / Akt pathway in muscle cells and thus phosphorylating downstream proteins. The activity of mTOR (mammalian target of rapamycin) by PI3K / Akt signaling is recognized as a central growth signaling mechanism that integrates various growth signals in cells. Activation of mTOR activates two subtargets, 4EBP1 (4E-binding protein) and p70S6K (phosphorylated 70-kDa ribosomal S6 kinase), which induce muscle protein synthesis to increase muscle mass (The Korea Journal of Sports Science 30: 1551-1561, 2011, J Biol. Chem 278: 40717-40722, 2003).
mTOR 외에도 근원세포 세포의 분화와 근육 형성은 다양한 인자들에 의해 조절된다 (cell Mol Life Sci 70: 4117-4130, 2013). 그 중, myoD는 근육 분화와 관련된 특이적 유전자의 발현을 개시하여, 중간엽줄기세포(mesenchymal stem cell)가 근원세포(myoblast)로 분화하는 것을 유도한다. MyoD에 의해 조절되는 미오게닌과 MHC(myosin heavy chain)는 근원세포의 융합(fusion)을 유도하여, 근관세포 (myotube)와 근섬유가 형성되도록 한다. 이 같은 과정을 통해 형성된 근섬유는 다발을 이루어 최종적으로 근육을 형성하게 된다 (Cell Mol Life Sci 70: 4117-4130, 2013; Sci Signal 6: re2, 2013). In addition to mTOR, differentiation and muscle formation of myocytes is regulated by a variety of factors (cell Mol Life Sci 70: 4117-4130, 2013). Among them, myoD initiates the expression of specific genes related to muscle differentiation, inducing mesenchymal stem cells to differentiate into myoblasts. Myogenin and myosin heavy chain (MHC), which are controlled by MyoD, induce fusion of myoblasts, leading to the formation of myotubes and muscle fibers. Muscle fibers formed through this process are bundled to finally form muscles (Cell Mol Life Sci 70: 4117-4130, 2013; Sci Signal 6: re2, 2013).
정상 조건 하에서 원시 줄기세포 (primary stem cell)로서의 휴지상태의 위성세포(quiescent satellite cell)는 연속적으로 증식 및 분화를 진행한다. 손상된 근육은 근원세포로 지칭되는 근원성 위성세포(myogenic satellite cells) 증식을 활성화하는 다양한 성장인자를 분비한다. 활성화된 근원세포는 Myo D, Myf(myogenic factor)-5, 미오게닌 및 Mrf-4 과 같은 근원성 인자 (myogenic factor)를 유도한다. MyoD 및 Myf-5 는 근원 세포 계열 (myogenic lineage)에 특이적으로 발현되는 전사 인자로써, 근원세포 분화 개시에 중요한 역할을 수행한다. (Langley, B.; Thomas, M.; Bishop, A.; Sharma, M.; Gilmour, S.; Kambadur, R. J. Biol. Chem. 2002, 277, 49831). 특히, Myo D는 E 단백질, Mef-2 계열 단백질 및 전사 보조인자등의 비근육성 특이 인자와의 결합을 통하여 MHC 및 미오게닌과 같은 근원성 단백질 발현을 유도한다. Under normal conditions, the quiescent satellite cells as primary stem cells continue to proliferate and differentiate. Injured muscle secretes a variety of growth factors that activate the proliferation of myogenic satellite cells, called myocytes. Activated myoblasts induce myogenic factors such as Myo D, myf (myogenic factor) -5, myogenin and Mrf-4. MyoD and Myf-5 are transcription factors specifically expressed in myogenic lineage and play an important role in initiating myoblast differentiation. (Langley, B .; Thomas, M .; Bishop, A .; Sharma, M .; Gilmour, S .; Kambadur, R. J. Biol. Chem. 2002, 277 , 49831). In particular, Myo D induces the expression of myogenic proteins such as MHC and myogenin through binding to non-muscular specific factors such as E protein, Mef-2 family proteins and transcriptional cofactors.
신선초(Angelica keiskei)는 쌍떡잎 식물로 4-히드록시데리신(hydroxyderricin), 크산토안젤롤(xanthoangelol), 크산토안젤롤(xanthoangelol) E, 크산토안젤롤(xanthoangelol) D, 크산토안젤롤(xanthoangelol) F, 크산토안젤롤(xanthoangelol) B, 크산토케이스민(xanthokeismin) A, 이소바바찰콘(isobavachalcone) 등의 성분이 알려져 있으며, 감기, 천식, 당뇨병 등의 질병치료에도 효과가 있다고 알려져 있으며 명일엽, 일본명 아쉬타바 (Ashitaba) 등으로 불리우며, 안젤리카 케이스키(Angelica keiskei), 안젤리카 키우시나(Angelica kiusina) 등을 포함한다 Angelica keiskei is a dicotyledonous plant, 4-hydroxyderricin, xanthoangelol, xanthoangelol E, xanthoangelol D, and xanthoangelol D. Ingredients such as xanthoangelol F, xanthoangelol B, xanthokeismin A, and isobavachalcone are known, and are known to be effective in treating diseases such as colds, asthma and diabetes. It is called the Japanese ashitaba, the Japanese name Ashitaba, and includes Angelica keiskei , Angelica kiusina , and the like.
그러나, 문헌 어디에도 신선초 추출물을 유효성분으로 함유하는 근육관련 질환의 치료 효과에 대하여 개시되거나 교시된 바가 없다. However, none of the literature discloses or teaches the therapeutic effect of muscle-related diseases containing fresh vinegar extract as an active ingredient.
이에 본 발명자들은 근육관련 질환에 효과적인 예방 및 치료제를 개발하기 위한 연구의 일환으로 신선초 추출물을 대상으로 (1) myoD 전사활성을 측정하는 근원세포 분화 효능 평가법 (실험예 1)을 통하여 MyoD 전사 활성을 유의적으로 증가시키는지, 또는 웨스턴 블롯팅 분석을 통해 분화된 C2C12 세포에서 MHC 발현을 증가시키는지 검토하여, (2) 근원세포 분화(myoblast differentiation)를 유도하는 실험 (실험예 2)을 통하여 시료 처리에 의해 실린더 형(cylinder-shaped) 다핵성 근관세포(multinucleated myotubes) 로의 분화가 농도 의존적으로 유도되었다. 또한 다핵성 근관세포(multinuclear myotubes)의 수가 증가하는 것을 확인하였다. 이러한 상기 실험 결과는 본 발명의 신선초 추출물 및 이로부터 분리된 화합물 4-hydroxyderricin, xanthoangelol, xanthoangelol , xanthoangelol D, xanthoangelol F, xanthoangelol B, xanthokeismin A, isobavachalcone이 긴장감퇴증, 근위축증, 근이영양증, 근육 퇴화, 근경직증, 근위축성 축삭경화증, 근무력증, 악액질 및 노인성근육감소증 등의 근육 질환 치료제 또는 보조제로 사용 가능함을 확인하고 본 발명을 완성하였다.In this regard, the present inventors have conducted MyoD transcriptional activity through a myogenic cell differentiation efficacy evaluation method (Experimental Example 1) to measure myoD transcriptional activity in fresh vinegar extract as part of a study to develop an effective prophylactic and therapeutic agent for muscle-related diseases. Whether significantly increased, or increased MHC expression in differentiated C2C12 cells by Western blotting analysis, and (2) the sample through the experiment to induce myoblast differentiation (Experimental Example 2) Treatment induced concentration-dependent differentiation into cylinder-shaped multinucleated myotubes. In addition, the number of multinuclear myotubes was increased. The results of the above experiments showed that the fresh vinegar extract of the present invention and the compound 4-hydroxyderricin, xanthoangelol, xanthoangelol, xanthoangelol D, xanthoangelol F, xanthoangelol B, xanthokeismin A, isobavachalcone, tension dystrophy, muscular dystrophy, muscular dystrophy, muscular dystrophy The present invention was completed by confirming that it can be used as a therapeutic agent or adjuvant for muscle diseases such as hypertrophy, muscular dystrophy, ataxia, myasthenia, cachexia and senile muscular dystrophy.
본 발명의 과제는 신선초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 근육관련 질환의 예방 및 치료용 약학 조성물을 제공한다.An object of the present invention to provide a pharmaceutical composition for the prevention and treatment of muscle-related diseases containing fresh vinegar extract or a compound isolated therefrom as an active ingredient.
또한 본 발명은 신선초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 근육관련 질환의 예방 및 개선용 건강기능식품을 제공한다.In another aspect, the present invention provides a functional food for the prevention and improvement of muscle-related diseases containing fresh vinegar extract or a compound isolated therefrom as an active ingredient.
본원에서 정의되는 신선초는 안젤리카 케이스키(Angelica keiskei), 안젤리카 키우시나(Angelica kiusina) 등의 동속식물의 뿌리, 줄기, 전초 잎, 바람직하게는, 뿌리 또는 전초를 포함함을 특징으로 한다. Fresh vines as defined herein are characterized by comprising roots, stems, outpost leaves, preferably roots or outposts of the same plant, such as Angelica keiskei , Angelica kiusina , and the like.
본원에서 정의되는 신선초 추출물은 신선초 조추출물, 신선초 조추출물로부터 정제된 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 포함함을 특징으로 한다.Fresh vinegar extract as defined herein is characterized in that it comprises a fresh vinegar crude extract, a polar solvent soluble extract or a non-polar solvent soluble extract purified from the crude vinegar extract.
*본원에서 정의되는 조추출물은 정제수를 포함한 물, 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물 또는 물 및 에탄올 혼합용매, 보다 바람직하게는 에탄올에 가용한 추출물임을 특징으로 한다.The crude extract as defined herein is a solvent selected from water containing purified water, lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, butanol, or a mixed solvent thereof, preferably water or a mixed solvent of water and ethanol, more preferably Is characterized in that the extract available in ethanol.
본원에서 정의되는 비극성용매 가용 추출 분획물은 본원의 조추출물로부터 헥산, 메틸렌 클로라이드, 클로로포름, 또는 에틸아세테이트 용매에 가용한 추출물만을 정제한 비극성 용매에 가용한 추출 분획물들을 포함한다.Non-polar solvent soluble extraction fractions as defined herein include those extraction fractions available in non-polar solvents that refine only the extracts available in hexane, methylene chloride, chloroform, or ethyl acetate solvents from the crude extracts herein.
본원에서 정의되는 극성용매 가용 추출물은 상기 조추출물로부터 비극성용매 가용분획물들을 제거하고 남은 물, 메탄올, 부탄올 또는 이들의 혼합용매로부터 선택되어진 용매에 가용한 추출 분획물을 포함한다.The polar solvent soluble extract as defined herein includes an extract fraction soluble in a solvent selected from the remaining water, methanol, butanol or a mixed solvent thereof after removing the non-polar solvent soluble fractions from the crude extract.
본원에서 정의되는 신선초 추출물로부터 분리된 화합물은 이소바바찰콘(isobavachalcone, 화합물 1), 4-하이드록시데리신(4-hydroxyderiicin, 화합물 2), 크산토안젤롤(xanthoangelol E , 화합물 3), 크산토안젤롤 D(xanthoangelol D, 화합물 4), 크산토안젤롤(xanthoangelol, 화합물 5), 크산토안젤롤 F, (xanthoangelol F, 화합물 6), 크산토케이스민 A (Xanthokeismin A, 화합물 7), 1-[2, 4-디히드록시-3-(6,7-디히드록시-3,7-디메틸-2-옥테닐)페닐] 3-(4-히드록시페닐-2-프레펜-1-온 챨콘 (1-[2, 4-dihydroxy-3-(6,7-dihydroxy-3,7-dimethyl-2-octenyl)phenyl] 3-(4-hydroxyphenyl-2-prepen-1-onechalcone 화합물8), 1-[2-히드록시-3-(7-히드록시-3,7-디메틸l-2, 5-옥타디에닐)-4-메톡시페닐]-3-(4-히드록시페닐)-2-프로펜-1-온 챨콘 (1-[2-hydroxy-3-(7-hydroxy-3,7-dimethyl-2, 5-ocadienyl)-4-methoxyphenyl]-3-(4-hydroxyphenyl)-2-propen-1-one chalcone, 화합물 9), 크산토안젤롤 B(Xanthoangolol B, 화합물 10)을 포함한다. Compounds isolated from fresh vinegar extract as defined herein are isobavachalcone (compound 1), 4-hydroxyderiicin (compound 2), xanthoangelol E (compound 3), xantho Angelol D (xanthoangelol D, Compound 4), xanthoangelol (Compound 5), xanthoangelol F, (xanthoangelol F, Compound 6), xanthokesamine A (Xanthokeismin A, Compound 7), 1 -[2,4-dihydroxy-3- (6,7-dihydroxy-3,7-dimethyl-2-octenyl) phenyl] 3- (4-hydroxyphenyl-2-prefen-1- Onconcon (1- [2,4-dihydroxy-3- (6,7-dihydroxy-3,7-dimethyl-2-octenyl) phenyl] 3- (4-hydroxyphenyl-2-prepen-1-onechalcone compound 8) , 1- [2-hydroxy-3- (7-hydroxy-3,7-dimethyll-2, 5-octadienyl) -4-methoxyphenyl] -3- (4-hydroxyphenyl)- 2-propen-1-one checon (1- [2-hydroxy-3- (7-hydroxy-3,7-dimethyl-2, 5-ocadienyl) -4-methoxyphenyl] -3- (4-hydroxyphenyl)- 2-propen-1-one chalcone, compound 9), xanthoangelol B (Xant hoangolol B, compound 10).
본원에서 정의되는 신선초 추출물 및 화합물의 HPLC(High performance liquid chromatography)분석에는 메탄올(Methanol) 또는 아세트나이트릴(Acetenitrile) 등의 비극성 용매와 산성 수용매를 혼합하는 조건에서 분석한다. High performance liquid chromatography (HPLC) analysis of fresh vinegar extracts and compounds as defined herein is performed under conditions of mixing an acidic solvent with a nonpolar solvent such as methanol or acetenitrile.
본원에서 정의되는 근육관련 질환은 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근경직증, 근위축성 축삭경화증, 근무력증, 악액질 (cachexia) 및 노인성근육감소증(sarcopenia)으로 이루어진 군에서 선택되는 하나 이상의 근육질환, 구체적으로, 노인성근위축 또는 암으로 인한 근육관련 질환, 보다 구체적으로는, 노인성근 위축 또는 암으로 인한 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근경직증, 근위축성 축삭경화증, 근무력증, 악액질 (cachexia), 노인성근육감소증(sarcopenia) 및 근육소실증을 포함한다. Muscle-related disorders as defined herein include atony, muscular atrophy, muscular dystrophy, muscle degeneration, myopathy, muscular atrophy, ataxia, cachexia and sarcopenia At least one muscle disease selected from the group consisting of muscle specific diseases caused by senile muscular atrophy or cancer, more specifically, muscular atrophy due to senile muscular atrophy or cancer, muscular dystrophy, Muscle degeneration, myopathy, muscular dystrophy, ataxia, ataxia, cachexia, sarcopenia and muscular loss.
또한 본 발명은 신선초 추출물 또는 이로부터 분리된 화합물을 함유하는 암으로 인한 근육관련 질환의 예방 및 치료제 또는 항암 보조 치료제를 제공한다.The present invention also provides a prophylactic and anticancer adjuvant therapy or a therapeutic agent for muscle-related diseases caused by cancer containing fresh vinegar extract or a compound isolated therefrom.
또한, 본 발명은 신선초 추출물 또는 이로부터 분리된 화합물과 기존 항암제와의 조합을 유효성분으로 하는 암에 의한 근육관련 질환의 예방 및 치료용 약학조성물, 항암치료 보조제 또는 건강기능식품을 제공한다.The present invention also provides a pharmaceutical composition for preventing and treating muscle-related diseases caused by cancer, comprising a combination of Sinchocho extract or a compound separated therefrom and an existing anticancer agent, an anticancer adjuvant or a health functional food.
본원에서 정의되는 기존 항암제는 시클로포스파미드(Cyclophosphamide), 메토트랙세이트 (methotrexate), 5-플루오로우라실(fluorouracil), 독소루비신(Doxorubicin), 무스틴(Mustine), 비크리스틴(vincristine), 프로카바진(procarbazine), 프레드니솔론(prednisolone), 블레오마이신(bleomycin), 빈블라스틴(vinblastine), 다카르바진(dacarbazine), 에토포시드 (etoposide), 시스플라틴(cisplatin), 에피루비신(Epirubicin), 시스풀라틴(cisplatin), 카페시타빈(capecitabine), 옥살리플라틴(oxaliplatin) 등을 포함한다.Existing anticancer agents as defined herein include cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, mustine, vicristine, procarba Procarbazine, prednisolone, bleomycin, vinblastine, dacarbazine, etoposide, cisplatin, epirubicin, cispool Cisplatin, capecitabine, oxaliplatin and the like.
본원에서 정의되는 암질환는 백혈병, 림프종, 골수종, 골수이형성증후군, 유방암, 두경부암, 식도암, 위암, 대장암(=결장암), 직장암, 항문암, 간세포간암, 담관암, 담낭암, 췌장암, 폐암(비소세포성 폐암, 소세포성 폐암), 흉선암, 신장암, 방광암, 전립선암, 고환암, 난소암, 자궁경부암, 육종, 위장관 기질성 종양(GIST, 기스트), 원발부위불명암, 중피종, 흑색종, 신경내분비 종양, 피부암, 혈액암 등을 포함한다.Cancer diseases as defined herein include leukemia, lymphoma, myeloma, myelodysplastic syndrome, breast cancer, head and neck cancer, esophageal cancer, gastric cancer, colon cancer (= colon cancer), rectal cancer, anal cancer, hepatocellular cancer, bile duct cancer, gallbladder cancer, pancreatic cancer, lung cancer (non-small cell Sex lung cancer, small cell lung cancer), thymic cancer, kidney cancer, bladder cancer, prostate cancer, testicular cancer, ovarian cancer, cervical cancer, sarcoma, gastrointestinal stromal tumor (GIST), primary site unknown cancer, mesothelioma, melanoma, Neuroendocrine tumors, skin cancers, hematological cancers, and the like.
이하, 본 발명을 더욱 상세히 설명한다. Hereinafter, the present invention will be described in more detail.
본 발명의 추출물들은 하기와 같은 제조방법으로 수득될 수 있다. Extracts of the present invention can be obtained by the preparation method as follows.
예를 들어, 이하, 본 발명을 상세히 설명한다.For example, the present invention will be described in detail below.
본 발명의 신선초 추출물은 하기와 같이 제조될 수 있다. 건조된 신선초를 세척 및 세절 후 정제수를 포함한 물, 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물 및 에탄올 혼합용매, 보다 바람직하게는 30~100% 에탄올을 수회 섞은 다음에 30℃ 내지 150℃, 바람직하게는 50℃ 내지 100℃의 온도에서 30분 내지 48시간, 바람직하게는 24시간 내지 36시간 동안 초음파 추출법, 열수 추출법, 상온 추출법 또는 환류추출법, 바람직하게는 상온추출법을 약 1 내지 20회, 바람직하게는 2 내지 10회 반복 수행하여 얻은 추출액을 여과, 감압 농축, 및 건조하여 본 발명의 조추출물을 얻을 수 있다. Fresh vinegar extract of the present invention can be prepared as follows. After washing and rinsing the dried fresh vinegar, a solvent selected from water including purified water, lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol and butanol, or a mixed solvent thereof, preferably a mixed solvent of water and ethanol, more preferably 30 ~ 100% ethanol several times and then ultrasonic extraction, hydrothermal extraction, room temperature extraction for 30 minutes to 48 hours, preferably 24 to 36 hours at a temperature of 30 ℃ to 150 ℃, preferably 50 ℃ to 100 ℃ or The crude extract of the present invention can be obtained by filtering, concentrating under reduced pressure, and drying the extract obtained by reflux extraction, preferably at room temperature extraction, about 1 to 20 times, preferably 2 to 10 times.
또한, 본 발명의 극성용매 또는 비극성용매 가용 추출물은 상기에서 얻은 조추출물 중량의 약 0.0005 내지 500배, 바람직하게는 0.05 내지 5배 부피 (v/w%)의 물을 가한 후, n-헥산, 메틸렌 클로라이드, 에틸 아세테이트 및 부탄올을 이용한 통상적인 분획과정을 수행하여 n-헥산, 메틸렌 클로라이드, 에틸 아세테이트 등의 비극성 용매에 가용한 비극성 용매 가용 추출 분획물; 및 부탄올, 물 등의 극성용매에 가용한 극성용매 가용 추출 분획물들을 각각 수득할 수 있다.In addition, the polar or non-polar solvent soluble extract of the present invention is added to the water of about 0.0005 to 500 times, preferably 0.05 to 5 times the volume (v / w%) of the crude extract obtained above, n-hexane, Non-polar solvent soluble extract fractions which are available in non-polar solvents such as n-hexane, methylene chloride, ethyl acetate by performing a conventional fractionation process using methylene chloride, ethyl acetate and butanol; And polar solvent soluble extraction fractions soluble in polar solvents such as butanol and water, respectively.
본 발명의 화합물은 하기와 같이 제조될 수 있다. 예를 들어, 상기에서 수득한 신선초 조추출물을 에틸에테르로 비극성물질을 분획한다. 에틸아세테이트 가용분획물을 n-헥산 100%을 이동상으로 유출을 시작하여 아세톤(Acetone)으로 극성을 높이면서 유출시켜 극성을 증가시키는 방법을 이용하여 실리카겔 오픈 컬럼크로마토그래피, 플래쉬 컬럼크로마토그래피, RP C18 컬럼크로마토그래피 또는 Diaion HP-20 컬럼크로마토그래피 등의 크로마토그래피를 이용한 정제방법을 선택적으로 수회 반복 수행하여 본 발명의 화합물들을 각각 정제 및 수득할 수 있다. The compounds of the present invention can be prepared as follows. For example, the crude fresh extract obtained above is fractionated with ethyl ether. Silica gel open column chromatography, flash column chromatography, RP C18 column using the method of increasing the polarity by starting the distillation of ethyl acetate soluble fraction with n-hexane to mobile phase and increasing the polarity to acetone (Acetone). Purification using chromatography or chromatography such as Diaion HP-20 column chromatography may be performed several times selectively to purify and obtain the compounds of the present invention, respectively.
본 발명자들은 상기 제조방법으로 수득되는 추출물을 대상으로 한 (1) myoD 전사활성(transcriptional activity)을 측정하는 근원세포의 분화촉진 효능 평가법(실험예 1)을 통하여 MyoD 전사 활성(transcriptional activity)을 유의적으로 증가시키고 분화된 C2C12 세포에서의 MHC 발현을 증가시킴을 확인하였으며, (2) 근원세포 분화(myoblast differentiation) 에 미치는 영향실험 (실험예 2)을 통하여 신선초 추출물 처치에 의하여 실린더 형(cylinder-shaped) 다핵성 근관세포(multinucleated myotubes) 수가 증가되었고, 근원세포 분화를 통한 근관세포 형성을 촉진시킴을 입증하여 상기 조성물을 근육질환의 예방 및 치료용 약학조성물 또는 건강기능식품으로 유용함을 확인하였다 The present inventors pay attention to MyoD transcriptional activity (Experimental Example 1) through the differentiation promoting efficacy evaluation method (Experimental Example 1) of measuring the myoD transcriptional activity of the extract obtained by the above production method (Experimental Example 1). It was confirmed that MHC expression was increased in the C2C12 cells, and (2) the effect of myoblast differentiation on the myoblast differentiation (Experimental Example 2). shaped) increased the number of multinucleated myotubes, and proved to promote myotube formation through myoblast differentiation, confirming that the composition is useful as a pharmaceutical composition or health functional food for the prevention and treatment of muscle diseases.
따라서, 본 발명은 상기 제조방법으로 수득된 신선초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 근육관련 질환의 예방 및 치료용 약학조성물 또는 건강기능식품을 제공한다.Accordingly, the present invention provides a pharmaceutical composition or health functional food for preventing and treating muscle-related diseases containing the fresh vinegar extract obtained by the above method or a compound isolated therefrom as an active ingredient.
본 발명의 화합물은 당해 기술분야에서 통상적인 방법에 따라 약학적으로 허용 가능한 염 및 용매화물로 제조될 수 있다. The compounds of the present invention can be prepared with pharmaceutically acceptable salts and solvates according to methods conventional in the art.
약학적으로 허용 가능한 염으로는 유리산(free acid)에 의해 형성된 산부가염이 유용하다. 산부가염은 통상의 방법, 예를 들면 화합물을 과량의 산 수용액에 용해시키고, 이 염을 메탄올, 에탄올, 아세톤 또는 아세토니트릴과 같은 수혼화성 유기 용매를 사용하여 침전시켜서 제조한다. 동일한 몰량의 화합물 및 물 중의 산 또는 알코올(예, 글리콜 모노메틸에테르)을 가열하고 이어서 상기 혼합물을 증발시켜서 건조시키거나, 또는 석출된 염을 흡인 여과시킬 수 있다.As the pharmaceutically acceptable salt, acid addition salts formed by free acid are useful. Acid addition salts are prepared by conventional methods, for example by dissolving a compound in an excess of aqueous acid solution and precipitating the salt using a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Equal molar amounts of the compound and acid or alcohol (eg, glycol monomethylether) in water can be heated and the mixture can then be evaporated to dryness or the precipitated salts can be suction filtered.
이 때, 유리산으로는 유기산과 무기산을 사용할 수 있으며, 무기산으로는 염산, 인산, 황산, 질산, 주석산 등을 사용할 수 있고 유기산으로는 메탄술폰산, p-톨루엔술폰산, 아세트산, 트리플루오로아 세트산, 시트르산, 말레인산(maleic acid), 숙신산, 옥살산, 벤조산, 타르타르산, 푸마르산, 만데르산, 프로피온산(propionic acid), 구연산(citric acid), 젖산(lactic acid), 글리콜산(glycollic acid), 글루콘산(gluconic acid), 갈락투론산, 글루탐산, 글루타르산(glutaric acid), 글루쿠론산(glucuronic acid), 아스파르트산, 아스코르빈산, 카본산, 바닐릭산 및 히드로 아이오딕산 등을 사용할 수 있다.In this case, organic acids and inorganic acids may be used as the free acid, and hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, and the like may be used as the inorganic acid, and methanesulfonic acid, p -toluenesulfonic acid, acetic acid, and trifluoroacetic acid may be used as the organic acid. , Citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid (gluconic acid), galacturonic acid, glutamic acid, glutaric acid (glutaric acid), glucuronic acid (glucuronic acid), aspartic acid, ascorbic acid, carbonic acid, vanic acid and hydroiodic acid may be used.
또한, 염기를 사용하여 약학적으로 허용 가능한 금속염을 만들 수 있다. 알칼리 금속 또는 알칼리토 금속염은, 예를 들면 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리토 금속 수산화물 용액 중에 용해하고, 비 용해 화합물염을 여과한 후 여액을 증발, 건조시켜 얻는다. 이때, 금속염으로서는 특히 나트륨, 칼륨 또는 칼슘염을 제조하는 것이 제약상 적합하며, 또한 이에 대응하는 은염은 알칼리 금속 또는 알칼리토 금속염을 적당한 은염(예, 질산은)과 반응시켜 얻는다.Bases can also be used to make pharmaceutically acceptable metal salts. An alkali metal or alkaline earth metal salt is obtained by, for example, dissolving a compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the non-soluble compound salt, and then evaporating and drying the filtrate. At this time, as the metal salt, it is particularly suitable to prepare sodium, potassium or calcium salt, and the corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (for example, silver nitrate).
본 발명의 화합물의 약학적으로 허용 가능한 염은, 달리 지시되지 않는 한, 본 발명의 화합물에 존재할 수 있는 산성 또는 염기성기의 염을 포함한다. 예를 들면, 약학적으로 허용 가능한 염으로는 히드록시기의 나트륨, 칼슘 및 칼륨염이 포함되며, 아미노기의 기타 약학적으로 허용 가능한 염으로는 하이드로브로마이드, 황산염, 수소 황산염, 인산염, 수소 인산염, 이수소 인산염, 아세테이트, 숙시네이트, 시트레이트, 타르트레이트, 락테이트, 만델레이트, 메탄설포 네이트(메실레이트) 및 p-톨루엔설포네이트(토실레이트) 염이 있으며, 당업계에서 알려진 염의 제조 방법이나 제조과정을 통하여 제조될 수 있다. Pharmaceutically acceptable salts of the compounds of the invention include salts of acidic or basic groups which may be present in the compounds of the invention, unless otherwise indicated. For example, pharmaceutically acceptable salts include sodium, calcium and potassium salts of the hydroxy group, and other pharmaceutically acceptable salts of the amino group include hydrobromide, sulfate, hydrogen sulphate, phosphate, hydrogen phosphate, dihydrogen Phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p -toluenesulfonate (tosylate) salts. It can be prepared through.
본 발명의 조성물은, 조성물 총 중량에 대하여 상기 추출물 또는 화합물을 0.01 내지 99% 중량으로 포함한다.The composition of the present invention comprises 0.01 to 99% by weight of the extract or compound relative to the total weight of the composition.
그러나 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고, 환자의 상태 및 질환의 종류 및 진행 정도에 따라 변할 수 있다.However, the composition as described above is not necessarily limited thereto, and may vary according to the condition of the patient and the type and extent of the disease.
본 발명의 추출물 또는 화합물을 포함하는 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.Compositions comprising extracts or compounds of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명에 따른 추출물 또는 화합물을 포함하는 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 이에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물 또는 화합물에 적어도 하나 이상의 부형제 적어도 면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스 (sucrose) 또는 락토오스 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Compositions comprising extracts or compounds according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods Carriers, excipients and diluents that may be included in the formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one or more excipients in at least one of the excipients, cotton, starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 추출물 또는 화합물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 추출물 또는 화합물은 1일 0.01 mg/kg 내지 10 g/kg으로, 바람직하게는 1 mg/kg 내지 1 g/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 그러므로 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the extracts or compounds of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract or compound is preferably administered at 0.01 mg / kg to 10 g / kg, preferably 1 mg / kg to 1 g / kg per day. Administration may be administered once a day or may be divided several times. Therefore, the above dosage does not limit the scope of the present invention in any aspect.
본 발명의 조성물은 마우스, 생마우스, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구 및 직장, 또는 정맥 등의 방법을 통하여 투여할 수 있다. The composition of the present invention can be administered to mammals such as mice, live mice, livestock, humans, etc. by various routes. All modes of administration can be anticipated, for example, by oral and rectal or intravenous methods.
본 발명은 또한 상기 신선초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 노인성근위축증 또는 악액질 치료제를 제공하며, 이러한 치료제는 노인성근위축증 또는 악액질의 병용요법에서 체중 변화나 식욕 회복의 개선 효과를 위한 것으로서, 악액질 치료에서 항암제 단독투여보다는 본 발명의 조성물을 이용한 병용요법을 제공한다.The present invention also provides a therapeutic agent for senile muscular dystrophy or cachexia containing the fresh vinegar extract or a compound isolated therefrom as an active ingredient, and the therapeutic agent is for improving the effect of weight change or appetite recovery in combination therapy with senile muscular atrophy or cachexia. In addition, the present invention provides a combination therapy using the composition of the present invention rather than an anticancer agent alone in cachexia treatment.
또한, 본 발명은 신선초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 근육관련 질환의 예방 및 개선을 위한 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for the prevention and improvement of muscle-related diseases containing a fresh vinegar extract or a compound isolated therefrom as an active ingredient.
본원에서 정의되는 "건강기능식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.As defined herein, "health functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functional" means It means ingestion for the purpose of obtaining useful effects on health use such as nutrient control or physiological action on structure and function.
본 발명의 근육관련 질환의 예방 및 개선을 위한 건강기능식품은, 조성물 총 중량에 대하여 상기 추출물 또는 화합물을 0.01 내지 95%, 바람직하게는 1 내지 80% 중량백분율로 포함한다.The dietary supplement for the prevention and improvement of the muscle-related diseases of the present invention comprises the extract or compound in an amount of 0.01 to 95%, preferably 1 to 80% by weight, based on the total weight of the composition.
더욱이, 본 발명의 조성물은 근육관련 질환의 치료 및 개선을 목적으로 한 건강기능식품 또는 건강보조식품일 수 있다. Furthermore, the composition of the present invention may be a dietary supplement or dietary supplement for the purpose of treating and improving muscle-related diseases.
또한, 근육관련 질환의 예방 및 개선을 위한 목적으로 산제, 과립제, 정제, 캡슐제, 환제, 현탁액, 에멀젼, 시럽 등의 약학 투여형태 또는 티백제, 침출차, 건강 음료 등의 형태인 건강기능식품으로 제조 및 가공이 가능하다.In addition, as a health functional food in the form of a pharmaceutical dosage form such as powders, granules, tablets, capsules, pills, suspensions, emulsions, syrups or tea bags, leaching tea, health drinks for the purpose of preventing and improving muscle-related diseases. Manufacturing and processing are possible.
또한, 본 발명은 신선초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 근육관련 질환의 예방 및 개선용 건강보조식품을 제공한다.The present invention also provides a dietary supplement for the prevention and improvement of muscle-related diseases containing fresh vinegar extract or a compound isolated therefrom as an active ingredient.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수성분으로서 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제 (타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등)) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖ 당 일반적으로 약 1~20 g, 바람직하게는 약 5~12 g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. have. The proportion of the natural carbohydrate is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
또한, 본 발명은 신선초 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 근육관련 질환의 예방 및 개선용 식품 또는 식품첨가제를 제공한다.The present invention also provides a food or food additive for the prevention and improvement of muscle-related diseases containing fresh vinegar extract or a compound isolated therefrom as an active ingredient.
본 발명에 따른 추출물 또는 화합물을 식품첨가물로 사용할 경우, 상기 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다. When the extract or compound according to the present invention is used as a food additive, the extract may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, etc., includes all of the health food in the conventional sense.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다. In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
또한, 본 발명의 추출물 또는 화합물은 목적 질환이 예방 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물 또는 화합물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖을 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.In addition, the extract or compound of the present invention may be added to food or beverage for the purpose of preventing the disease of interest. At this time, the amount of the extract or compound in the food or beverage may be added at 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml Can be added.
본 발명의 신선초 추출물 및 화합물들을 대상으로 (1) myoD 전사활성(transcriptional activity)을 측정하는 근원세포의 분화촉진 효능 평가법(실험예 1)을 통하여 MyoD 전사 활성을 유의적으로 증가시키고 분화된 C2C12 세포에서의 MHC 발현유도를 통하여 근육세포로의 분화를 촉진함을 확인하였으며; (2) 근원세포 분화(myoblast differentiation) 에 미치는 영향실험 (실험예 2)을 통하여 시료 처치에 의하여 실린더형(cylinder-shaped) 다핵성 근관세포(multinucleated myotubes)로 분화가 농도의존적으로 유도되었고, 다핵성 근관세포 (multinucleated myotubes)의 수가 증가함을 확인하였는 바, 이러한 상기 실험 결과는 본 발명의 시료들이 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근경직증, 근위축성 축삭경화증, 근무력증, 악액질 (cachexia) 및 노인성근육감소증(sarcopenia) 등의 근육 질환 치료제 또는 보조제로 사용 가능함을 확인함으로써, 상기 조성물을 근육질환의 예방 및 치료용 약학조성물, 건강기능식품 및 건강보조식품 등으로 유용함을 확인하였다.(1) Significantly increased MyoD transcriptional activity and differentiated C2C12 cells through (1) MyoD transcriptional activity evaluation method (Experimental Example 1) of myoD extracts and compounds of the present invention to measure myoD transcriptional activity. It was confirmed that the induction of MHC expression in promotes the differentiation into muscle cells; (2) Influence on myoblast differentiation (Experimental Example 2) Induced differentiation into cylinder-shaped multinucleated myotubes in a concentration-dependent manner by multiplying sample through multi-nucleus. It was confirmed that the number of multinucleated myotubes increased, these experimental results indicate that the samples of the present invention are atony, muscular atrophy, muscular dystrophy, muscle degeneration, myopathy , By confirming that the composition can be used as a therapeutic agent or adjuvant for muscle diseases such as muscular dystrophy, ataxia, myasthenia, cachexia and sarcopenia, the composition for the prevention and treatment of muscle diseases, health functional foods and It was found to be useful as a health supplement.
도 1은 본 발명 추출물에서부터 분리한 화합물의 구조를 나타낸 도이다.
도 2는 본 발명 추출물에 포함되어 있는 화합물 2와 화합물 5의 함량을 구하기 위한 HPLC 크로마토그램을 나타내는 도이다.
도 3은 본 발명 추출물의 myoD 전사활성화(transactivation)을 나타낸 도이다. (데이타는 mean ± SD으로 표기하여 *p < 0.001 의미함).
도 4는 본 발명 추출물의 MHC (myosin heavy chain)의 단백질 발현에 미치는 영향을 나타낸 도이다(데이타는 mean ± SD으로 표기하여 *p< 0.05 의미함).
도 5는 다핵성 근관섬유에서의 MHC (myosin heavy chain) 발현에 미치는 영향을 나타낸 도이다.
도 6은 본 발명 추출물에 포함되어있는 화합물들의 myoD 전사활성화(transactivation) 및 MHC (myosin heavy chain) 발현에 미치는 영향을 나타낸 도이다 (데이타는 mean ± SD으로 표기하여 *p < 0.001 의미함).
도 7은 본 발명 추출물에 포함되어 있는 화합물들의 MHC (myosin heavy chain)의 단백질 발현에 미치는 영향을 나타낸 도이다. (데이타는 mean ± SD으로 표기하여 *p< 0.05 의미함)
도 8는 본 발명 추출물에 포함되어 있는 화합물 중 챨콘(chalcone) 화합물 1, 화합물 2, 화합물 5, 화합물 6의 MHC (myosin heavy chain)의 단백질 발현에 미치는 영향을 나타낸 도이다 (데이타는 mean ± SD으로 표기하여 *p< 0.05 의미함).
도 9는 다핵성 근관섬유에서의 MHC (myosin heavy chain) 발현에 미치는 영향을 나타낸 도이다.1 is a diagram showing the structure of a compound isolated from the extract of the present invention.
2 is a diagram showing an HPLC chromatogram for determining the content of
Figure 3 is a diagram showing myoD transactivation of the extract of the present invention. (Data is expressed as mean ± SD, meaning * p <0.001).
Figure 4 is a diagram showing the effect on the protein expression of MHC (myosin heavy chain) of the extract of the present invention (data denoted by mean ± SD means * p <0.05).
5 is a diagram showing the effect on the expression of MHC (myosin heavy chain) in multinucleated myotubes.
Figure 6 is a diagram showing the effect on the myoD transactivation and MHC (myosin heavy chain) expression of the compounds contained in the extract of the present invention (data denotes mean ± SD * p <0.001 means).
Figure 7 is a diagram showing the effect on the protein expression of MHC (myosin heavy chain) of the compounds contained in the extract of the present invention. (Data is expressed as mean ± SD, meaning * p <0.05.)
8 is a diagram showing the effect on the protein expression of MHC (myosin heavy chain) of chalcone (chalcone)
9 is a diagram showing the effect on the expression of MHC (myosin heavy chain) in multinucleated myotubes.
이하, 본 발명을 하기 참고예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by the following Reference Examples and Experimental Examples.
단, 하기 참고예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 참고예 및 실험예에 의해 한정되는 것은 아니다.However, the following Reference Examples and Experimental Examples are merely illustrative of the present invention, the content of the present invention is not limited by the following Reference Examples and Experimental Examples.
실시예 1. 신선초 조추출물의 제조Example 1. Preparation of fresh vinegar crude extract
건조된 신선초 (생동농산, 서울 한국, 숙명여자대학 약초표본실 보존 표본 SPH 1502) 3kg에 100% 에탄올 6ℓ를 넣고 24시간 동안 상온추출한 후, 여과하고 감압 조건하에서 농축하였다. 농축된 에탄올 추출물은 감압 조건하에서 냉동 건조기 (ScanVac, Labogene)로 동결 건조하여 300g의 신선초 에탄올 추출물 분말(이하, AKCE라 함)을 얻어 다음 실험에 사용하였다. 6 liters of 100% ethanol was added to 3 kg of dried fresh vinegar (Saengdong Nongsan, Korea, Seoul, Korea), and 100% ethanol was extracted for 24 hours, filtered and concentrated under reduced pressure. The concentrated ethanol extract was lyophilized with a freeze dryer (ScanVac, Labogene) under reduced pressure to obtain 300 g of fresh ethanol extract powder (hereinafter referred to as AKCE) and used for the next experiment.
실시예 2. 신선초 분획물의 제조예 Example 2 Preparation Example of Fresh Herb Fraction
실시예 1에서 얻은 건조된 신선초 에탄올 추출물 300g에 정제수 500ml을 가하여 현탁하고 이 현탁물에 n-헥산 500ml를 가하여 분획하여 n-헥산 가용 분획물로 분획하고, 남은 물 현탁물에 에틸아세테이트 600ml 및 부탄올 600ml을 순차적으로 가하여 분획하고 각각 감압 건조하여 n-헥산 가용분획물(이하, AKH라 함), 에틸아세테이트 가용분획물 (이하, AKE라 함) 및 부탄올 가용분획물(이하, AKB라 함)을 14g, 7.8g, 30g을 각각 얻어 동결건조하였다. To 300 g of dried fresh ethanol extract obtained in Example 1, 500 ml of purified water was added and suspended. Were added sequentially and fractionated and dried under reduced pressure, respectively, to obtain n-hexane soluble fraction (hereinafter referred to as AKH), ethyl acetate soluble fraction (hereinafter referred to as AKE) and butanol soluble fraction (hereinafter referred to as AKB) to 14 g and 7.8 g. , 30g were each obtained and lyophilized.
실시예 3. 신선초 추출물로부터 활성 화합물의 분리Example 3. Isolation of Active Compounds from Fresh Creeper Extract
활성물질의 동정을 위하여, 하기 실험에서, 가장 활성이 높은 분획 중 n-헥산과 에틸아세테이트 가용분획물 21.8g을 대상으로 실리카겔 컬럼크로마토그래피법을 n-Hexane/acetone 경사법(gradient system, 50:1→1:2) 조건으로 수행하여 9개 소분획물 (subfraction)을 얻고,To identify the active substances, silica gel column chromatography was performed on n-Hexane / acetone gradient system (50: 1) for 21.8 g of n-hexane and ethyl acetate soluble fraction in the most active fractions. → 1: 2) to obtain nine subfractions,
이중 분획물 (F3)을 대상으로 추가로 실리카겔 컬럼크로마토그래피법을 Hexane/ethylacetate 경사법(gradient system, 10:1→1:1) 용매 조건으로 수행하고, 이 분획물 중 F3-2를 대상으로 추가로 역상 컬럼크로마토크래피법 MeOH 경사법(gradient system, 50%→100%) 용매 조건으로 수행하였다. 이 중 분획물(F3-2-5)를 대상으로 추가로 실리카겔 컬럼크로마토그래피법을 Hexane/ethylacetate 경사법(gradient system, 20:1→1:1) 용매 조건으로 수행하고, 분획물 F3-2-5-3을 대상으로 실리카겔 컬럼크로마토그래피법을 Hexane/(10% isopropanol) ethylacetate을 7:1 용매 조건으로 수행하여 하기 화합물 2 (4-hydroxyderricin, 35 mg)을 수득하였다. Silica gel column chromatography was performed on the double fraction (F3) under Hexane / ethylacetate gradient system (10: 1 → 1: 1) solvent conditions, and F3-2 of the fraction was further analyzed. Reversed phase chromatography chromatography MeOH gradient (50% → 100%) was carried out under the solvent conditions. Among them, fractions (F3-2-5) were further subjected to silica gel column chromatography under Hexane / ethylacetate gradient (20: 1 → 1: 1) solvent conditions, and fractions F3-2-5. Silica gel column chromatography on -3 was performed by Hexane / (10% isopropanol) ethylacetate under 7: 1 solvent conditions to obtain the following compound 2 (4-hydroxyderricin, 35 mg).
이중 분획물 (F5)를 대상으로 추가로 실리카겔 컬럼크로마토그래피법을 Hexane/(10% isopropanol) ethylacetate을 7:1 용매 조건으로 수행하고, 이 중 분획물 F5-2를 역상 컬럼크로마토크래피법 MeOH 경사법(gradient system, 60%→100%) 용매 조건으로 수행하여, 하기 화합물 5 (xanthoangelol, 25 mg)를 수득하였다.Silica gel column chromatography on double fraction (F5) was further performed with Hexane / (10% isopropanol) ethylacetate under 7: 1 solvent conditions, and fraction F5-2 was subjected to reverse phase column chromatography with MeOH gradient. (gradient system, 60% → 100%) was carried out under solvent conditions to give the following compound 5 (xanthoangelol, 25 mg).
(A) 화합물 2: 4-하이드록시데리신(4-hydroxyderricin)(A) Compound 2: 4-hydroxyderricin
성상: 노란색 파우더Appearance: Yellow Powder
1H-NMR (400MHz, CDCl3) : δ 1.69 (3H, s, H-5”), 1.81(3H, s, H-4”), 3.40(2H, D, J=6.8Hz, H-1”), 3.92(3H, s, OMe), 5.24(1H, tq, J=7.2, 1.6Hz, H-2”), 6.51(1H, d, J=8,8Hz, H-5’), 6.89(2H, d, J=8.8Hz, H-3, H-5), 7.47(1H, d, J=15.6Hz, H-α), 7.56(2H, J=8.8Hz, H-2, H-6), 7.80(1H, d, J=8.8Hz, H-6’), 7.83(1H, d, J=15.6Hz, H-β)1 H-NMR (400 MHz, CDCl 3): δ 1.69 (3H, s, H-5 ”), 1.81 (3H, s, H-4”), 3.40 (2H, D, J = 6.8 Hz, H-1 ”) , 3.92 (3H, s, OMe), 5.24 (1H, tq, J = 7.2, 1.6 Hz, H-2 ”), 6.51 (1H, d, J = 8,8 Hz, H-5 '), 6.89 (2H , d, J = 8.8Hz, H-3, H-5), 7.47 (1H, d, J = 15.6Hz, H-α), 7.56 (2H, J = 8.8Hz, H-2, H-6) , 7.80 (1H, d, J = 8.8 Hz, H-6 '), 7.83 (1H, d, J = 15.6 Hz, H-β)
13C-NMR (100MHz, CDCl3) : δ 17.8 (C-4”), 21.7(C-1”), 25.8(C-5”), 55.8(Ome), 102.1(C-5’), 114.6(C-1’), 116.0(C-3, C-5), 117.6(C-3’), 118.1(C-α), 122.0(C-2”), 127.7(C-1), 129.2(C-6’), 130.5(C-2, C-6), 131.9(C-3”), 144.1(C-β), 158.1(C-4), 163.0(C-2’), 163.3(C-4’), 192.4(C=0)13C-NMR (100MHz, CDCl3): δ 17.8 (C-4 ”), 21.7 (C-1”), 25.8 (C-5 ”), 55.8 (Ome), 102.1 (C-5 '), 114.6 (C -1 '), 116.0 (C-3, C-5), 117.6 (C-3'), 118.1 (C-α), 122.0 (C-2 ”), 127.7 (C-1), 129.2 (C- 6 '), 130.5 (C-2, C-6), 131.9 (C-3 ”), 144.1 (C-β), 158.1 (C-4), 163.0 (C-2'), 163.3 (C-4 '), 192.4 (C = 0)
(B) 화합물 5: 젠토엘겔롤(Xanthoangelol)(B) Compound 5: Xanthoangelol
성상: 노란색 파우더Appearance: Yellow Powder
1H-NMR (400MHz, CDCl3) : 1.50(3H, s, H-10”), 1.57(3H, s, H-9”), 1.73(3H, s, H-8”), 1.59(2H, m, H-4”), 2.00(2H, m, H-5”), 3.36(2H, d, J=6.8Hz, H-1”), 5.00(1H, m, H-6”), 5.22(1H, m, H-2”), 6.36(1H, d J=8.8Hz, H-5’), 6.79(2H, d, J=8.4Hz, H-3, H-5), 7.36(1H, d, J=15.2Hz, H-α), 7.45(2H, d, J=8.4Hz, H-2, H-6), 7.60(1H, d, J=8.8Hz, H-6’), 7.70(1H, d, J=15.2Hz, H-β)1 H-NMR (400 MHz, CDCl 3): 1.50 (3H, s, H-10 ”), 1.57 (3H, s, H-9”), 1.73 (3H, s, H-8 ”), 1.59 (2H, m , H-4 ”), 2.00 (2H, m, H-5”), 3.36 (2H, d, J = 6.8 Hz, H-1 ”), 5.00 (1H, m, H-6”), 5.22 ( 1H, m, H-2 ”), 6.36 (1H, d J = 8.8 Hz, H-5 '), 6.79 (2H, d, J = 8.4 Hz, H-3, H-5), 7.36 (1H, d, J = 15.2 Hz, H-α, 7.45 (2H, d, J = 8.4 Hz, H-2, H-6), 7.60 (1H, d, J = 8.8 Hz, H-6 '), 7.70 (1H, d, J = 15.2 Hz, H-β)
13C-NMR (100MHz, Cd3OD) : δ 15.9(C-10”), 17.38(C-9”), 21.46(C-8”), 26.5(C-5”), 39.6(C-4”), 107.2(C-5’), 113.4(C-1’), 115.3(C-3’), 115.8(C-3, C-5), 117.4(C-α), 121.7(C-2”), 124.2(C-6”), 126.5(C-1), 128.8(C-6’), 130.3(C-2, C-6), 131.2(C-7”), 135.9(C-3”), 144.0(C-β), 159.4(C-4), 161.8(C-2’), 163.6(C-4’), 192.1(C=0)13C-NMR (100MHz, Cd3OD): δ 15.9 (C-10 ”), 17.38 (C-9”), 21.46 (C-8 ”), 26.5 (C-5”), 39.6 (C-4 ”), 107.2 (C-5 '), 113.4 (C-1'), 115.3 (C-3 '), 115.8 (C-3, C-5), 117.4 (C-α), 121.7 (C-2 ”), 124.2 (C-6 ”), 126.5 (C-1), 128.8 (C-6 '), 130.3 (C-2, C-6), 131.2 (C-7”), 135.9 (C-3 ”), 144.0 (C-β), 159.4 (C-4), 161.8 (C-2 '), 163.6 (C-4'), 192.1 (C = 0)
실험예 1. 신선초 추출물의 성분분석Experimental Example 1. Component Analysis of Sinchocho extract
상기 실시예의 신선초 에탄올 추출물의 화합물 2와 화합물5의 함량을 알아보기 위해 HPLC분석을 진행하였다.HPLC analysis was performed to determine the contents of
실시예 1에서 얻은 신선초 에탄올 추출물과 실시예 3에서 얻은 화합물 2와 화합물 5를 80% 메탄올 조건에서 컬럼 (C18 4.6mm x 150mm, 5 μm, cat. 5020-01124, GL sciences Inc.)를 사용하여 360nm의 파장에서 분석하였다. 이를 통해 추출물에 포함된 화합물 2와 화합물 5의 함유율을 분석하였다.The fresh ethanol extract of Example 1 and the
1-1. 실험 과정1-1. Experiment process
HPLC는 80% 메탄올 조건에서 4.6 x 150mm, 5um 컬럼을 이용하여 360nm에서 측정하였다. 신선초 에탄올 추출물과 화합물 2와 5을 각각 1 mg/ml, 0.1 mg/ml, 0.01 mg/ml로 시료를 만든 후 5μl, 2μl, 3μl를 주입하여 크로마토크램을 얻어 각 피크의 면적을 이용하여 추출물에 포함된 화합물 2와 5의 함량을 구하였다.HPLC was measured at 360 nm using a 4.6 x 150 mm, 5um column at 80% methanol. Samples of fresh ethanol extract and
1-2. 실험 결과1-2. Experiment result
본 실험 결과, 신선초 추출물 5μg에 함유되어 있는 화합물 2와 화합물 5는 각각 0.195 μg, 0.295 μg으로 확인하였고, 이를 토대로 함량을 구하였을 때 화합물 2와 화합물 5는 각각 3.8%, 5.8%로 확인하였다. (도 2)As a result, the
실험예 1. 신선초 추출물의 근원세포의 분화촉진 효능 평가Experimental Example 1.Evaluation of Differentiation Promoting Effect of Myofibrillar Radix Cells
상기 실시예의 신선초 에탄올 추출물의 근원세포의 분화(myogenic effect)에 미치는 영향을 알아보기 위하여 문헌에 기재된 대로, 마우스 근원세포주인 C2C12 세포에 myoD-반응성 유전자와 루시퍼라제가 융합된 리포터 벡터(MyoD-responsive reporter 4RTK-luc)를 삽입하고, 추출물 처리에 따른 루시퍼라제 활성도변화를 측정함으로써 myoD 전사활성을 분석하여 근원세포의 분화촉진 효능을 평가하였다 (J. Biol. Chem 2004, 279, pp.52643). As described in the literature, the reporter vector (MyoD-responsive) in which myoD-reactive gene and luciferase were fused to C2C12 cells, a mouse myoblast cell line, to investigate the effect on the myogenic effect of ethanol extract of fresh ethanol extract of the above example. reporter 4RTK-luc) was inserted and myoD transcriptional activity was analyzed by measuring luciferase activity change according to extract treatment to evaluate the differentiation-promoting efficacy of myoblasts ( J. Biol. Chem 2004, 279 , pp. 52643).
1-1. 실험 과정1-1. Experiment process
티미딘 키나제 프로모터(thymidine kinase promoter)에 융합된 4개의 부위(E-box sites)를 포함하는 자체제작한 리포터 벡터(MyoD-responsive reporter 4RTK-luciferase construct)를 MyoD 전사 활성을 평가하는데 사용하였다. A self-made reporter vector (MyoD-responsive reporter 4RTK-luciferase construct) comprising four E-box sites fused to a thymidine kinase promoter was used to assess MyoD transcriptional activity.
골격근 성장연구를 위한 모델 세포로 간주되는 마우스 근원 세포주 C2C12에 일시적으로 myoD 발현 벡터 (myoD expression vector) 및 리포터 벡터 (MyoD-responsive reporter 4RTK-luc) (숙명여자대학교 약학대학 배규운 교수 제공)를 문헌에 기재된 방법으로 형질 주입(transfection)시켰다 (Eur J Histochem. 2004, 48, 223-33). A myoD expression vector and a reporter vector (MyoD-responsive reporter 4RTK-luc) (provided by Prof. Kyu-Woon Bae, College of Pharmacy, Sookmyung Women's University) Transfection was carried out by the method described in ( Eur J Histochem. 2004, 48, 223-33).
형질 주입 24 시간 후, 세포들에 신선초 추출물 (10, 100, 1000 ng/ml)을 처리한 후, 추가로 24 시간 배양하였다. After 24 hours of transfection, the cells were treated with fresh vinegar extract (10, 100, 1000 ng / ml), and further cultured for 24 hours.
배양한 세포는 인산 완충 생리 식염수로 2회 세척 후, 리포터 용해 버퍼로 (Cat#. E1941, Promega) 용해시킨 다음 세포 용해물을 5 μl를 취하여 루시퍼라제 분석용 96-웰 플레이트 (Cat# 31196, SPL)에 분주하고 루시퍼라제 기질 (Dual Luciferase Reporter Assay System, Cat# E1910, Promega) 30 μl를 더해 흡광도를 측정하였다. The cultured cells were washed twice with phosphate buffered saline solution, lysed with reporter lysis buffer (Cat #. E1941, Promega), and then 5 μl of the cell lysate was taken into a 96-well plate for luciferase analysis (Cat # 31196, SPL) and absorbance was measured by adding 30 μl of Luciferase Substrate (Dual Luciferase Reporter Assay System, Cat # E1910, Promega).
β-갈락토시다제 (galactosidase) 활성은 세포 용해물에 Stop and Glo 시약 (Ccat# E1910, Promega)을 30 μl 더하여 흡광도를 측정하였다. 데이터는 β-갈락토시다제 (galactosidase) 활성으로 나눈 상대적 루시페라제 활성 (relative luciferase activity (RLU))으로 표시하고 평균(mean)±SD으로 표기하였다.β-galactosidase activity was measured for absorbance by adding 30 μl of Stop and Glo reagent (Ccat # E1910, Promega) to the cell lysate. Data are expressed as relative luciferase activity (RLU) divided by β-galactosidase activity and expressed as mean ± SD.
1-2. 실험 결과1-2. Experiment result
본 실험 결과, 대조군 세포에서의 루시퍼라제 활성을 1로 하였을 때, 신선초 추출물을 10 ng/ml 처리하였을 때는 3배, 100 ng/ml 처리하였을 때는 4배, 1000ng/ml 처리하였을 때는 13배 각각 증가되어, 신선초 추출물은 농도 의존적으로 MyoD 전사 활성(transcriptional activity)을 증가시킴을 확인하였다(표 1 및 도 3). As a result of the experiment, when luciferase activity in control cells was set to 1, 3 times of fresh vinegar extract was treated with 10 ng / ml, 4 times with 100 ng / ml, and 13 times with 1000 ng / ml. In addition, it was confirmed that the fresh vinegar extract increased MyoD transcriptional activity (Table 1 and Figure 3) in a concentration-dependent manner.
실험예 2. 신선초추출물의 근원세포 분화(myoblast differentiation) 에 미치는 영향Experimental Example 2. Effect of fresh vinegar extract on myoblast differentiation
상기 실시예의 신선초 추출물의 근원세포 분화(myoblast differentiation) 에 미치는 영향을 알아보기 위하여 문헌에 기재된 평가법을 이용하여 하기와 같이 실험을 수행하였다 (Chem. Biol. Interact. 2016, 248, 60). In order to determine the effect on myoblast differentiation of fresh vinegar extract of the above example, the experiment was performed using the evaluation method described in the literature as described below ( Chem. Biol. Interact. 2016, 248 , 60).
근원세포가 근관섬유로 분화하는 과정에서, 단핵성 근원세포 (mononucleated myoblast)는 보다 신장되어(elongated) 실린더-형 근세포(cylinder-shaped myocytes)로 변화된다. 활성화된 근세포에서는 MyoD, myogenic factor (Myf)-5, 미오게닌, 그리고 myogenic regulatory factor (Mrf)-4등의 발현이 증가하여 여러 근육 분화에 관련된 유전자들을 활성화시켜 근관섬유로의 분화를 촉진한다. 생성된 근세포들은 서로 융합하여 다핵성 근관섬유(multinucleated myotubes)를 형성하는데, 이 때 근관섬유에서는 근육분화 마커인 Mrf-4, 미오게닌 또는 MHC 발현이 증가하게 된다 (Histochem. Cell Biol. 2012, 138, p.187; J. Cell Physiol. 2010, 224, p7). In the process of differentiation of myoblasts into myotubes, mononucleated myoblasts are elongated and transformed into cylinder-shaped myocytes. In activated myocytes, the expression of MyoD, myogenic factor (Myf) -5, myogenin, and myogenic regulatory factor (Mrf) -4 is increased to activate genes involved in different muscle differentiation and promote differentiation into myotube fibers. . The resulting myocytes fuse with each other to form multinucleated myotubes, which increase the expression of Mrf-4, myogenin, or MHC, a muscle differentiation marker ( Histochem. Cell Biol. 2012 , 138, p. 187; J. Cell Physiol. 2010 , 224, p7).
따라서 MHC는 근육 분화 말기의 마커로 알려져 있으며, 최종 분화된 근관세포(terminally differentiated myotubes)에서 MHC 발현 수준을 분석하여 근원세포의 분화촉진 (myogenic differentiation) 능력의 수준을 예상할 수 있다. Therefore, MHC is known as a marker of late stage of muscle differentiation, and the level of myogenic differentiation ability of myoblasts can be predicted by analyzing the level of MHC expression in terminally differentiated myotubes.
그러므로 본 실험에서는 MHC 단백질 발현을 측정하여 근원세포가 근관섬유로의 분화가 진행되는 지표로 활용하였다.Therefore, in this experiment, MHC protein expression was measured and used as an indicator of the differentiation of myoblasts into myotubes.
2-1. 실험 과정2-1. Experiment process
C2C12 근원세포에 신선초 추출물(10, 100, 1000 ng/ml)을 처리하여 분화 배지 (differentiation medium, 2% horse serum-containing DMEM, Cat# 11965-084, Gibco)상에서 3일간 처리하면서 분화를 유도하였다. C2C12 myoblasts were treated with fresh vinegar extract (10, 100, 1000 ng / ml) to induce differentiation by treatment on differentiation medium (2% horse serum-containing DMEM, Cat # 11965-084, Gibco) for 3 days. .
분화된 세포에서 세포 용해물을 획득하여 웨스턴 블롯법을 통해 MHC 단백질의 발현 수준을 평가 (도 4A)하였고, 마우스 항(mouse anti)-MHC, Santa cruze) 및 항 마우스 (anti-mouse IgG2b Alexa-fluor 568)로 면역 염색법을 수행하여 MHC 발현을 평가하였다 (도 2B).Cell lysates were obtained from differentiated cells to evaluate the expression level of MHC protein by Western blot (FIG. 4A), mouse anti-MHC, Santa cruze and anti-mouse IgG2b Alexa- Immunostaining was performed with fluor 568) to evaluate MHC expression (FIG. 2B).
웨스턴 블롯 분석(Western blot analysis)을 위해 약 3 X 104 의 근원세포를 60 mm 플레이트에서 24 시간 배양한 후, 분화 배지에 각 시료를 첨가하여 3 일간 분화시킨 후, 세포 용해 버퍼로 (lysis buffer, 25 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), and protease inhibitor cocktail (Calbiochem, Darmstadt, Germany) 단백질 추출물(Protein extracts)을 얻고 25 μg의 단백질 추출물로 SDS-polyacrylamide gel electorphoresis (PAGE)를 실시하고, polyvinylidene fluoride (PVDF) membranes로 이동시켰다. 이 블롯에 일차 마우스 항-MHC를 4 °C에서 12 시간 동안 결합시키고, 이어서 Horseradish peroxidase가 연결된 항 마우스 2차 항체 (goat anti-mouse IgG-HRP, Enzo)를 결합한 후, 화학발광으로 MHC 단백질량을 분석하였다. 이 때 적재 대조군(loading control)으로 pan-cadherin(Cat# 3678, Sigma)을 사용하였다. For Western blot analysis, approximately 3
위와 같은 방법으로 각각의 시료를 첨가한 분화 배지에서 근원세포를 분화시켜, 면역 형광염색 (immunofluorescence staining)을 실시하였다. 각각의 분화 배지를 제거하고, 인산완충 생리식염수로 2회 세척 후, 4% paraformaldehyde로 20 분간 고정하였다. 다시 인산완충 생리식염수로 2회 세척하고, 0.1% tritonX-100에 20 분간 처리하였다. 인산완충 생리식염수로 2회 세척하고, 5% horse serum 용액에서 블로킹한 후 마우스 항-MHC (MAB4470, R&D systems)를 넣고 12 시간 동안 4°C에서 반응시켰다. 반응 후 3회 이상 인산완충 생리식염수로 세척한 후 Alexa Flouor 568-결합된 2차 항 마우스 (A-21144, MicoProbes)와 DAPI (D9542, Sigma)를 이용하여 MHC 발현을 분석하였다. In the same manner as described above, the source cells were differentiated in the differentiation medium to which each sample was added, and immunofluorescence staining was performed. Each differentiation medium was removed, washed twice with phosphate buffered saline, and fixed for 20 minutes with 4% paraformaldehyde. Again washed with phosphate buffered saline twice, and treated with 0.1% tritonX-100 for 20 minutes. After washing twice with phosphate buffered saline, blocking in 5% horse serum solution, mouse anti-MHC (MAB4470, R & D systems) was added and reacted at 4 ° C for 12 hours. After the reaction, the cells were washed with phosphate buffered saline at least three times, and then MHC expression was analyzed using Alexa Flouor 568-bound secondary anti-mouse (A-21144, MicoProbes) and DAPI (D9542, Sigma).
MHC-양성 근관세포 (positive myotubes)의 면역형광(Immunofluorescence) 결과는 적색으로 시각화하고 DAPI-표지된 핵은 청색으로 시각화하였다. Immunfluorescence results of MHC-positive myotubes were visualized in red and DAPI-labeled nuclei were visualized in blue.
다핵성 근관세포 (Multinucleated ( >5)MHC-expressing myotubes)는 무작위적으로 선택된 부위에서 산출하였다 (Scale bar = 200 mm). MHC-양성이며, 다핵성(multinucleated)인 근관세포수를 분석한 후, 총세포수 (total cells)를 적용하여 각 세포에서의 상대적 multinucleated-MHC양성 근관세포수(MHC-positive myotubes)를 산출하였다. Multinucleated ( > 5) MHC-expressing myotubes were generated at randomly selected sites (Scale bar = 200 mm). After analyzing MHC-positive and multinucleated myotubes, total cells were used to calculate the relative multinucleated-MHC-positive myotubes in each cell. .
2-2. 실험 결과(표 2 내지 표 3)2-2. Experimental Results (Tables 2 to 3)
도 4A에서는 신선초 추출물의 MHC 발현에 대한 효과를 측정하였다. 근원세포의 분화 배지에 10, 100, 1000 ng/ml의농도로 처리하여 근관섬유로 3 일간 분화시키고 세포를 수확하여, 근관섬유로의 분화 마커인 MHC의 단백질 발현을 웨스턴 블롯팅 분석법으로 분석하였다. In FIG. 4A, the effect on MHC expression of fresh vinegar extract was measured. The differentiation medium of myoblasts was treated at concentrations of 10, 100, 1000 ng / ml and differentiated into root canal fibers for 3 days, and the cells were harvested. The protein expression of MHC, a marker for differentiation into root canal fibers, was analyzed by Western blotting analysis. .
분석 결과, 대조군 세포에서의 MHC 발현을 1로 하였을 때, 신선초 추출물을 10 ng/ml 처리하였을 때는 3배, 100 ng/ml 처리하였을 때는 4배, 1000ng/ml 처리하였을 때 5배 각각 증가되었다. As a result, when MHC expression was 1 in the control cells, the fresh vinegar extract was increased three times when treated with 10 ng / ml, four times when treated with 100 ng / ml, and five times when treated with 1000 ng / ml.
신선초 추출물은 Myo D 전사 활성화(transcriptional activation) 실험 결과와 일치하게, 분화된 C2C12 세포에서의 myoD 뿐만 아니라 MHC의 발현을 증가시킴을 확인하였다.In accordance with the results of Myo D transcriptional activation experiments, the extract of Sinchochoa was found to increase the expression of MHC as well as myoD in differentiated C2C12 cells.
이러한 상기 실험 결과는 본 발명의 신선초 추출물이 농도 의존적으로 근원세포분화(myogenic differentiation)를 촉진시킴을 확인하였다. These experimental results confirmed that the fresh vinegar extract of the present invention promotes myogenic differentiation in a concentration-dependent manner.
도 5에서는, 항(anti)-MHC 항체(antibodies) 및 DAPI을 이용한 면역형광 염색법(immunofluorescence staining)으로 추출물의 근육분화 활성을 측정하였다.In Figure 5, the muscle differentiation activity of the extract was measured by immunofluorescence staining with anti-MHC antibodies (antibodies) and DAPI.
도 5에 나타난 바와 같이, 증가된 적색형광(red-fluorescence)은 신선초 추출물이 C2C12 세포에서의 MHC 발현을 농도 의존적으로 촉진함을 의미하며, DAPI 염색(counter staining)을 통해 MHC의 발현되는 실린더 형(cylinder-shaped) 근관세포가 다핵성(multinucleated)임을 확인할 수 있었다. As shown in FIG. 5, increased red-fluorescence means that the fresh herb extract promotes MHC expression in C2C12 cells in a concentration-dependent manner, and the cylindrical form of MHC expressed through DAPI counter staining. (cylinder-shaped) root canal cells were confirmed to be multinucleated (multinucleated).
상기 실험에서 근원세포 분화도는 다핵성 (multinucleated MHC-양성 세포)의 백분율로 표기하였다. 그 결과, 신선초 추출물은 1000 ng/ml의 낮은 농도에서도, 근관세포에서의 MHC 발현과 실린더 형(cylinder-shaped) 다핵성 근관세포(multinucleated myotubes) 수를 증가시킴을 알 수 있었으며 근육 세포 분화를 활성화함을 입증하였다. Myoblast differentiation in this experiment was expressed as a percentage of multinucleated MHC-positive cells. As a result, it was found that the extract of Sinchochoa increased MHC expression and the number of cylinder-shaped multinucleated myotubes in the root canal cells even at a low concentration of 1000 ng / ml and activated muscle cell differentiation. Proved.
실험예 3. 신선초 화합물들의 근원세포의 분화촉진 효능 평가Experimental Example 3. Evaluation of Differentiation Promoting Effect of Myofibrillar Cells
상기 실시예의 신선초에 함유되어 있는 화합물들의 근원세포의 분화(myogenic effect)에 미치는 영향을 알아보기 위하여 문헌에 기재된 대로, 마우스 근원세포주인 C2C12 세포에 myoD-반응성 유전자와 루시퍼라제가 융합된 리포터 벡터(MyoD-responsive reporter 4RTK-luc)를 삽입하고, 화합물 처리에 따른 루시퍼라제 활성도변화를 측정함으로써 myoD 전사활성을 분석하여 근원세포의 분화촉진 효능을 평가하였다 (J. Biol. Chem 2004, 279, 52643). In order to examine the effect on the myogenic effect of myoblasts of the compounds contained in fresh vinegar of the above embodiment, as described in the literature, a reporter vector fused with myoD-reactive gene and luciferase to C2C12 cells, a mouse myoblast cell line ( MyoD-responsive reporter 4RTK-luc) was inserted and myoD transcriptional activity was analyzed by measuring luciferase activity change according to compound treatment to evaluate the differentiation-promoting effect of myoblasts ( J. Biol. Chem 2004, 279 , 52643).
3-1. 실험 과정3-1. Experiment process
실험과정 1-1과 동일한 방법으로 실시하였다.The experiment was carried out in the same manner as in Experiment 1-1.
3-2. 실험 결과3-2. Experiment result
본 실험 결과, 대조군 세포에서의 루시퍼라제 활성을 1으로 하였을 때, 신선초 화합물을 0.1 nm 처리하였을 때 화합물 2와 화합물 5가 각각 21배, 13배로 활성을 나타내는 것을 확인하였다. 다른 화합물들 또한 MyoD 전사 활성(transcriptional activity)을 유의적으로 증가시킴을 확인하였다(표 4 및 도 6). As a result of the experiment, when luciferase activity in the control cell was set to 1, it was confirmed that the
실험예 4. Experimental Example 4. 신선초 화합물이 근원세포 분화(myoblast differentiation) 에 미치는 영향 Effect of Fresh Creeping Compounds on Myoblast Differentiation
상기 실시예의 신선초에 함유되어 있는 화합물의 근원세포 분화(myoblast differentiation) 에 미치는 영향을 알아보기 위하여 문헌에 기재된 평가법을 이용하여 하기와 같이 실험을 수행하였다 (Chem. Biol. Interact. 2016, 248, 60. ). In order to determine the effect on myoblast differentiation of the compound contained in fresh vinegar of the above example, the experiment was carried out as follows using the evaluation method described in the literature ( Chem. Biol. Interact. 2016 , 248 , 60 .).
본 실험에서는 MHC 단백질 발현을 측정하여 근원세포가 근관섬유로의 분화가 진행되는 지표로 활용하였다.In this experiment, MHC protein expression was measured and used as an indicator for the differentiation of myoblasts into myotubes.
4-1. 실험 과정4-1. Experiment process
실험과정 2-1과 동일하게 실시하였다.The same procedure as in Experiment 2-1 was conducted.
4-2. 실험 결과(표 5)4-2. Experimental Results (Table 5)
도 6에서는 신선초에 함유되어 있는 화합물들의 MHC 발현에 대한 영향을 나타내었다. 근원세포의 분화 배지에 0.1nm의 농도로 처리하여 근관섬유로 3 일간 분화시키고 세포를 수확하여, 근관섬유로의 분화 마커인 MHC의 단백질 발현을 웨스턴 블롯팅 분석법으로 분석하였다. Figure 6 shows the effect on the MHC expression of the compounds contained in fresh vinegar. Cells were harvested by differentiation of myoblasts in differentiation medium at a concentration of 0.1 nm for 3 days, and cells were harvested. Protein expression of MHC, a marker of differentiation into myotubes, was analyzed by Western blotting.
분석 결과, 대조군 세포에서의 MHC 발현을 1로 하였을 때, 화합물 2와 화합물 5를 처리하였을 때 각각, 발현된 MHC가 6배, 3배 증가되었다. As a result, when MHC expression was 1 in the control cells, when the
신선초에 함유되어 있는 화합물들은 Myo D 전사 활성화(transcriptional activation) 실험 결과와 일치하게, 분화된 C2C12 세포에서의 myoD 뿐만 아니라 MHC의 발현을 증가시킴을 확인하였다.Compounds contained in fresh vinegar were found to increase the expression of MHC as well as myoD in differentiated C2C12 cells, consistent with Myo D transcriptional activation experiments.
이러한 상기 실험 결과는 본 발명의 신선초에 함유되어 있는 화합물이 근원세포분화(myogenic differentiation)를 촉진시킴을 확인하였다. These experimental results confirmed that the compound contained in the fresh vinegar of the present invention promotes myogenic differentiation (myogenic differentiation).
실험예 5. 신선초 chalcone 화합물들의 근원세포 분화(myoblast differentiation) 에 미치는 영향Experimental Example 5. Effect on myoblast differentiation of chalcone compounds
상기 실시예의 신선초에 함유되어 있는 몇 종의 chalcone 화합물들의 근원세포 분화(myoblast differentiation) 에 미치는 영향을 알아보기 위하여 문헌에 기재된 평가법을 이용하여 하기와 같이 실험을 수행하였다 (Chem. Biol. Interact. 2016, 248, 60. ). In order to determine the effect on the myoblast differentiation of several kinds of chalcone compounds contained in fresh vinegar of the above example, the experiment was carried out as follows using the evaluation method described in the literature ( Chem. Biol. Interact. 2016) . , 248 , 60.).
본 실험에서는 MHC 단백질 발현을 측정하여 근원세포가 근관섬유로의 분화가 진행되는 지표로 활용하였다.In this experiment, MHC protein expression was measured and used as an indicator for the differentiation of myoblasts into myotubes.
4-1. 실험 과정4-1. Experiment process
실험과정 2-1과 동일하게 실시하였다.The same procedure as in Experiment 2-1 was conducted.
4-2. 실험 결과 (표 6 내지 표 7)4-2. Experimental Results (Tables 6-7)
도 8,9에서는 신선초에 함유되어 있는 몇 종의 chalcone 화합물들의 MHC 발현에 대한 영향을 나타내었다. 근원세포의 분화 배지에 0.1nm의 농도로 처리하여 근관섬유로 3 일간 분화시키고 세포를 수확하여, 근관섬유로의 분화 마커인 MHC의 단백질 발현을 웨스턴 블롯팅 분석법으로 분석하였다. 8 and 9 show the effect on the MHC expression of several kinds of chalcone compounds contained in fresh vinegar. Cells were harvested by differentiation of myoblasts in differentiation medium at a concentration of 0.1 nm for 3 days, and cells were harvested. Protein expression of MHC, a marker of differentiation into myotubes, was analyzed by Western blotting.
분석 결과, 대조군 세포에서의 MHC 발현을 1로 하였을 때, 챨콘(chalcone) 화합물의 처리에 의해 발현된 MHC가 3 - 5배 정도 증가되었다. As a result, when MHC expression in control cells was set to 1, MHC expressed by treatment with a chalcone compound increased by 3-5 times.
도 9에 나타난 바와 같이, 증가된 적색형광(red-fluorescence)은 신선초에 함유되어 있는 챨콘(chalcone)화합물들이 C2C12 세포에서의 MHC 발현을 촉진함을 의미하며, DAPI 염색(counter staining)을 통해 MHC의 발현되는 실린더 형(cylinder-shaped) 근관세포가 다핵성(multinucleated)임을 확인할 수 있었다. As shown in FIG. 9, increased red-fluorescence means that the chalcone compounds contained in fresh vines promote MHC expression in C2C12 cells, and MHC through DAPI counter staining. It was confirmed that the expressed cylindrical cylinder-shaped root canal cells are multinucleated.
하기에 본 발명의 시료 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자함이 아닌 단지 구체적으로 설명하고자함이다.Hereinafter, the preparation examples of the composition including the sample extract of the present invention, but the present invention is not intended to limit it, only intended to explain in detail.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
추출물 (AKCE) ------------------------------------------- 20 mgExtract (AKCE) ------------------------------------------- 20 mg
유당 --------------------------------------------------- 100 mgLactose ------------------------------------------------- -100 mg
탈크 ---------------------------------------------------- 10 mgTalc ------------------------------------------------- --- 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
분획물(AKH) -------------------------------------------- 10 mgFraction (AKH) -------------------------------------------- 10 mg
옥수수전분 -------------------------------------------- 100 mgCorn Starch -------------------------------------------- 100 mg
유당 -------------------------------------------------- 100 mgLactose ------------------------------------------------- -100 mg
스테아린산 마그네슘 ------------------------------------- 2 mgMagnesium Stearate ------------------------------------- 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예 3. 캅셀제의 제조 Formulation Example 3 Preparation of Capsule
분획물 (AKE) ------------------------------------------- 10 mgFraction (AKE) ------------------------------------------- 10 mg
결정성 셀룰로오스 --------------------------------------- 3 mgCrystalline Cellulose -------------------------------------- 3 mg
락토오스 --------------------------------------------- 14.8 mgLactose --------------------------------------------- 14.8 mg
마그네슘 스테아레이트 --------------------------------- 0.2 mgMagnesium Stearate --------------------------------- 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4 Preparation of Injection
분획물(AKB) -------------------------------------------- 10 mgFraction (AKB) -------------------------------------------- 10 mg
만니톨 ------------------------------------------------ 180 mgMannitol ------------------------------------------------ 180 mg
주사용 멸균 증류수 ----------------------------------- 2974 mgSterile Distilled Water for Injection ----------------------------------- 2974 mg
Na2HPO4,12H2O ------------------------------------------- 26 mgNa 2 HPO 4 , 12H 2 O ------------------------------------------ -26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2 ㎖) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예 5. 액제의 제조Formulation Example 5 Preparation of Liquid
추출물 (AKCE) ------------------------------------------- 20 mgExtract (AKCE) ------------------------------------------- 20 mg
이성화당 ------------------------------------------------- 10 gIsomerized sugar ------------------------------------------------ -10 g
만니톨 ---------------------------------------------------- 5 gMannitol ------------------------------------------------- --- 5 g
정제수 --------------------------------------------------- 적량Purified water ------------------------------------------------- -Appropriate
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ㎖으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to the conventional method of preparing a liquid solution, each component is added to the purified water to dissolve it, the lemon flavor is added appropriately, the above components are mixed, purified water is added, the whole is adjusted to 100 ml by the addition of purified water, and then filled in a brown bottle. The solution is prepared by sterilization.
제제예 6. 건강 식품의 제조Formulation Example 6 Preparation of Healthy Food
추출물 (AKCE) ---------------------------------------- 1000 ㎎ Extract (AKCE) ---------------------------------------- 1000 mg
비타민 혼합물 -------------------------------------------- 적량Vitamin Mixture -------------------------------------------- Proper
비타민 A 아세테이트 ------------------------------------- 70 ㎍ Vitamin A Acetate ------------------------------------- 70 μg
비타민 E ----------------------------------------------- 1.0 ㎎Vitamin E ----------------------------------------------- 1.0 Mg
비타민 B1 --------------------------------------------- 0.13 ㎎Vitamin B1 --------------------------------------------- 0.13 mg
비타민 B2 --------------------------------------------- 0.15 ㎎ Vitamin B2 --------------------------------------------- 0.15 mg
비타민 B6 ---------------------------------------------- 0.5 ㎎Vitamin B6 ---------------------------------------------- 0.5 mg
비타민 B12 --------------------------------------------- 0.2 ㎍Vitamin B12 --------------------------------------------- 0.2 μg
비타민 C ------------------------------------------------ 10 ㎎ Vitamin C ------------------------------------------------ 10 mg
비오틴 -------------------------------------------------- 10 ㎍Biotin ------------------------------------------------- 10 μg
니코틴산아미드 ----------------------------------------- 1.7 ㎎ Nicotinamide ----------------------------------------- 1.7 mg
엽산 ---------------------------------------------------- 50 ㎍Folic Acid ------------------------------------------------- --- 50 μg
판토텐산 칼슘 ------------------------------------------ 0.5 ㎎ Calcium Pantothenate ------------------------------------------ 0.5 mg
무기질 혼합물 -------------------------------------------- 적량Mineral mixture -------------------------------------------- Correct
황산제1철 --------------------------------------------- 1.75 ㎎ Ferrous Sulfate --------------------------------------------- 1.75 Mg
산화아연 ---------------------------------------------- 0.82 ㎎ Zinc Oxide ---------------------------------------------- 0.82 mg
탄산마그네슘 ------------------------------------------ 25.3 ㎎ Magnesium Carbonate ------------------------------------------ 25.3 mg
제1인산칼륨 --------------------------------------------- 15 ㎎ Potassium monophosphate --------------------------------------------- 15 Mg
*제2인산칼슘 --------------------------------------------- 55 ㎎ Dicalcium Phosphate --------------------------------------------- 55 mg
구연산칼륨 ---------------------------------------------- 90 ㎎ Potassium Citrate ---------------------------------------------- 90 mg
탄산칼슘 ----------------------------------------------- 100 ㎎ Calcium Carbonate ----------------------------------------------- 100 Mg
염화마그네슘 ------------------------------------------ 24.8 ㎎ Magnesium Chloride ------------------------------------------ 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.
제제예 7. 건강 음료의 제조Formulation Example 7 Preparation of Healthy Drink
화합물 1------------------------------------------------- 1000㎎
구연산 ------------------------------------------------- 1000 ㎎ Citric Acid ------------------------------------------------- 1000 mg
*올리고당 ------------------------------------------------- 100 g*oligosaccharide ------------------------------------------------ -100 g
매실농축액 ------------------------------------------------- 2 gPlum concentrate ------------------------------------------------ -2 g
타우린 ----------------------------------------------------- 1 gTaurine ------------------------------------------------- ---- 1 g
정제수를 가하여 ------------------------------------ 전체 900 ㎖Add purified water ------------------------------------ total 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated and then stored in the present invention For the preparation of healthy beverage compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a composition that is relatively suitable for the preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180125971A KR102022279B1 (en) | 2018-10-22 | 2018-10-22 | A composition comprising an extract of Angelica keiskei for treating and preventing muscle-related disorder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180125971A KR102022279B1 (en) | 2018-10-22 | 2018-10-22 | A composition comprising an extract of Angelica keiskei for treating and preventing muscle-related disorder |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170064440A Division KR102040119B1 (en) | 2017-05-25 | 2017-05-25 | A composition comprising the isolated compounds from an extract of Angelica keiskei for treating and preventing muscle-related disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180129707A KR20180129707A (en) | 2018-12-05 |
KR102022279B1 true KR102022279B1 (en) | 2019-09-18 |
Family
ID=64743621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180125971A KR102022279B1 (en) | 2018-10-22 | 2018-10-22 | A composition comprising an extract of Angelica keiskei for treating and preventing muscle-related disorder |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102022279B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102511861B1 (en) | 2022-10-14 | 2023-03-20 | 주식회사 함소아제약 | Composition for strengthening muscle strength comprising a complex extract of Angelica keiskei and Morus alba leaves |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102194345B1 (en) * | 2019-02-27 | 2020-12-22 | 종근당건강 주식회사 | Composition for Preventing or Treating Muscular disease containing Angelica gigas Nakai extract |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160017223A (en) * | 2014-08-01 | 2016-02-16 | 주식회사 풀무원 | Composition for muscle development and muscle fatigue recovery comprising Angelica keiskei extract and Red ginseng extract as active ingradients |
-
2018
- 2018-10-22 KR KR1020180125971A patent/KR102022279B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102511861B1 (en) | 2022-10-14 | 2023-03-20 | 주식회사 함소아제약 | Composition for strengthening muscle strength comprising a complex extract of Angelica keiskei and Morus alba leaves |
Also Published As
Publication number | Publication date |
---|---|
KR20180129707A (en) | 2018-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101416149B1 (en) | Composition comprising an extract of Curcuma longa L. or Curcuma aromatica L. isolated therefrom having IL-6 induced STAT3 inhibitory activity | |
KR102410619B1 (en) | A composition comprising the isolated compound 1 from an extract of alder tree for treating and preventing skeleton muscle-related disorder | |
KR101561552B1 (en) | Composition for preventing or treating cancer comprising lignan compound | |
KR101741017B1 (en) | Pharmaceutical composition comprising sesquiterpenoid for preventing or treating STAT3 mediated disease and use thereof | |
KR102022279B1 (en) | A composition comprising an extract of Angelica keiskei for treating and preventing muscle-related disorder | |
KR102006998B1 (en) | A pharmaceutical composition for preventing or treating IL-6-mediated disease, comprising extract, fraction, or compounds derived from Ampelopsis brevipedunculata | |
KR102132525B1 (en) | A composition comprising a tussilagone isolated from the extract of Tussilago farfara. for treating and preventing cancer disease | |
KR100902094B1 (en) | Pharmaceutical composition for the prevention and treatment of cancers containings extracts, fractions and isolated 2?arylbenzofuran compounds of Mori Cortex Radicis as an active ingredient | |
KR102002260B1 (en) | A composition comprising the compounds isolated from an extract of Allium sativum L. for treating and preventing muscle-related disorder | |
KR102040119B1 (en) | A composition comprising the isolated compounds from an extract of Angelica keiskei for treating and preventing muscle-related disorder | |
KR102566433B1 (en) | Composition for muscle diseases, preventing or treating Sarcopenia comprising silver skin of coffee extract or fractions thereof or compounds isolated from therefrom | |
KR102132126B1 (en) | A composition comprising 4-hydroxyderricin or xanthoangelol isolated from an extract of Angelica keiskei for treating and preventing cachexia or sarcopenia | |
KR20180131770A (en) | A composition comprising extract of Coptis chinensis F. for treating and preventing muscle-related disorder | |
KR20220152006A (en) | A composition for preventing, improving or treating bone disorder comprising extracts of oat | |
KR101972657B1 (en) | Composition comprising extract of Angelica decursiva Franchet et Savatieras or compounds isolated therefrom for preventing or treating osteoporosis | |
KR100784628B1 (en) | A compound having an effect of death for cancer cell and a pharmaceutical composition for preventing together with treating cancer disease containing thereof | |
KR101996184B1 (en) | Adjuvant of anti-cancer agent comprising and an extract of Allium sativum L. for treating and preventing cachexia | |
KR101965699B1 (en) | A composition comprising and an extract of Allium sativum L. for treating and preventing muscle-related disorder | |
KR20230046149A (en) | A composition comprising an extract of Alpinia officinarum or the isolated compound therefrom for treating and preventing skeleton muscle-related disorder | |
US20240115537A1 (en) | Composition for preventing or treating breast cancer comprising compound derived from dendropanax morbiferus | |
KR100701607B1 (en) | Composition comprising cudraflavanone A isolated from Cudrania tricuspidata CARR. showing topoisomerase ? inhibiting activity for the prevention and treatment of cancer disease | |
KR101848285B1 (en) | Composition comprising rhamnoarabinogalacturonan from mulberry fruit Oddi (Morous alba L.) as active ingredient for preventing or treating of obesity | |
KR20200131209A (en) | Pharmaceutical composition for prevention or treatment inflammatory diseases comprising comprising root extract Hovenia dulcis, or fractions thereof, or compounds isolated from therefrom | |
KR20200023234A (en) | Composition for preventing or treating cancer comprising compound represented by formula 1 | |
WO2014035060A1 (en) | Composition for preventing or treating cancer containing extracts of artocarpus altilis fruits, leaves, or stems, or fractions thereof as active ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |